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Abstract 
 Certain species of lactic acid bacteria produce and secrete bacteriocins, which are 
ribosomally synthesized antimicrobial peptides. These peptides recognize and kill target 
cells by rendering their membrane permeable for various small molecules. There has been an 
increased interest in lactic acid bacteria bacteriocins because of their potential use as food 
additives and pharmaceuticals. Plantaricin EF is a two-peptide bacteriocin produced by the 
lactic acid bacteria Lactobacillus plantarum C11. The two peptides constituting this 
bacteriocin are called Plantaricin E (PlnE) and Plantaricin F (PlnF). For optimal 
antimicrobial effect, the two peptides have to be present in equal molar amounts. Circular 
dichroism studies suggest that the peptides interact physically with each other upon contact 
with target membranes. The inter-peptide interactions between PlnE and PlnF are thought to 
be mediated by GxxxG motifs, which are located in their amphiphilic α-helical region. 
GxxxG motifs are known to confer helix-helix interactions between membrane-inserted 
polypeptides. In addition, tyrosine and tryptophan residues tend to be prominent in trans-
membrane proteins, especially in the parts of proteins exposed to the interface region of the 
membrane. It is believed that these aromatic residues enhance stability because of 
interactions with membrane-lipids in the interface region.   
 
To study the importance of GxxxG motifs in helix-helix interactions between PlnE and PlnF, 
the glycine-residues in PlnF have been altered by in vitro site-directed mutagenesis. The 
tyrosine and tryptophan residues in PlnF were also altered by in vitro site-directed 
mutagenesis, in order to investigate how PlnF will orient itself in target cell membranes. In 
order to do this, the gene encoding PlnF, plnF, and the gene encoding its cognate immunity 
protein, plnI, have been connected to the sakacin P leader-sequence, and cloned into the 
shuttle-vector pLPV111. The vector was transformed into the lactic acid bacteria 
Lactobacillus sake Lb790 containing the plasmid pSAK20. pLPV111 and pSAK20 are part 
of a heterologous expression system designed for expression of the many different 
bacteriocin. By using this expression system, PlnF is expressed separate from PlnE. This 
makes it easier to isolate and purify PlnF, as well as constructing and purifying the mutant 
version of PlnF, for subsequent structure and function analysis.  
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1. Introduction 
1.1 Antimicrobial Peptides 
All living animals have the need to protect themselves against the invading, 
pathogenic organisms they are exposed to every day. These are organisms such as enveloped 
viruses (i.e. HIV and herpes virus), bacteria, fungi and parasites, but also cancer cells 1. 
Several different defense-mechanisms have evolved, and antimicrobial peptides (AMPs) are 
important members of the host defense system. These small, cationic, ribosomally 
synthesized peptides are produced in many different tissue and cell types in various 
invertebrate, plant and animal species 2; 3; 4. Especially organs that are more prone to 
invading pathogens, such as the eyes, ears, mouth, esophagus, lungs, stomach, bone marrow 
and testicles produce antimicrobial peptides 5. Since invasion of a single bacterium can result 
in an infection in 24 hours, given a 50 min doubling time 1, the body is dependent on the 
innate immune system, which can respond rapidly to the infection. It has been suggested that 
antimicrobial peptides should be included as a part of the innate immune system 1. Even 
though they are not as specific as the immunoglobins of the adaptive immune system, they 
can be produced up to 100 times faster and also diffuse much faster, and with lower cost of 
energy 5; 6; 7. It is further evident that a single animal can produce more than 20 different 
antimicrobial peptides 1, for instance cows can produce as many as 36 different antimicrobial 
peptides of various classes and variants 8. 
 
Generally speaking, antimicrobial peptides consist of 12-50 amino acid residues, 50% or 
more of these residues are hydrophobic 1; 9. The peptides often have a net positive charge of 
+2 to +7, and low proportion of neutral polar and negatively charged amino acids, reflecting 
their ability to interact with negatively charged target membranes 10; 9; 1.  
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1.2 Bacteriocins 
Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria,  
that often, but not always, target and kill bacteria related to the bacteriocin-producing strain 
11; 10. Most bacteria produce only one bacteriocin, but some species can produce several 
different bacteriocins 12. Although descriptions of substances with bacteriocin-like activity 
first came in the late 19th century by Babes 13, the first documentation of the nature of a 
bacteriocin came in 1925 when Gratia demonstrated that an Escherichia coli (E. coli)-
produced substance, termed colicin, had the ability to inhibit growth of other E. coli strains14. 
Since then, many antimicrobial peptides have been identified and characterized in most 
bacterial strains, both Gram negative and Gram positive bacteria, and the collective term 
“bacteriocins”, which was originally coined for antimicrobial antibiotic proteins of the 
colicin type 15, was extended to also include non-colicin antimicrobial peptides produced by 
Gram positive bacteria 16.  
 
Most bacteriocins produced by the Gram negative bacteria are large proteins (>20 kDa) 10 
that range in size from about 200 to 800 amino acid residues 12. The most extensively studied 
bacteriocins produced by Gram negative bacteria are by far the E. coli-produced colicins. 
Killing-modes of colicins range from membrane pore formation to nuclease activity against 
DNA, rRNA and tRNA in target cells 12. Bacteriocins produced by Gram positive bacteria 
are most often peptides smaller than 6 kDa 10. These bacteriocins are more abundant and 
diverse than the bacteriocins produced by Gram negative bacteria, and they have a broader 
activity spectrum (i.e. kill a greater variety of bacteria-species) 16; 11. One of the key 
differences between the bacteriocins produced by Gram positive and Gram negative bacteria 
is that bacteriocin-production in Gram positive bacteria is not lethal to the producing cell, as 
apposed to what is the case for production in Gram negative bacteria. Whereas Gram 
negative cells generally rely on cell-lysis for release of bacteriocins, Gram positive bacteria 
have evolved transport systems to release their bacteriocins into the environment, the 
transport system consisting of either a bacteriocin-specific transporter or a sec-dependent 
pathway 17; 18; 12. Moreover, Gram positive bacteria produce an immunity protein that 
protects bacteriocin-producing bacteria from being killed by their own bacteriocin 19. 
In recent years, there has been a rapid spread of multi-resistant pathogenic bacteria due to the 
use of broad-spectrum antibiotics. Bacteriocins may provide a solution to this problem 
because of their specificity towards target cells and different killing-mechanism.   
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There has in recent years especially been much interest in and research on the bacteriocins 
produced by the Gram positive lactic acid bacteria (LAB), because these bacteria are non-
pathogenic and naturally inhabit the gut of humans and animals. LAB and the bacteriocins 
they produce are therefore considered safe for eukaryotes, and have thus a potential as 
biopreservatives in food and feed. The LAB-produced bacteriocin nisin has already been 
used as a food preservative for 30 years 20.  
 
The remainder of this introduction will focus on the LAB bacteriocins (defined in section 
1.3), and especially class IIb LAB bacteriocins, which plantaricin EF is categorized as.  
 
1.3 Classification of LAB Bacteriocins 
LAB bacteriocins are divided into three different classes based on their structure and 
function (Fig. 1.1) 21. The class I bacteriocins are the post-translationally modified peptide 
bacteriocins, class II bacteriocins are the unmodified peptide bacteriocins, while class III 
bacteriocins are the large, heat-labile protein bacteriocins.  
 
LAB 
bacteriocins
Class I:
Lantibiotics
Class II:
Unmodified heat-
stable bacteriocins
Class III:
Heat-labile 
protein 
bacterioc ins
Type A:
Elongated shaped 
molecules
Type B:
Globular 
molecules
Subclass IIa:
Pediocin-like 
bacteriocins
Subclass IIb:
Two-peptide 
bacteriocins
Subclass IIc:
Other peptide 
bacteriocins
 
Fig. 1.1: Classification of LAB bacteriocins. Class I bacteriocins are the lantibiotics, which are divided into 
two subclasses based on their structure. The class II bacteriocins are the unmodified, heat-stable peptide 
bacteriocins, and these are divided into three subclasses. The third class of bacteriocins are the heat-labile 
protein bacteriocins. 
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1.3.1 Class I Bacteriocins 
Class I bacteriocins, also known as lantibiotics, contain the unusual post-
translationally modified residues lanthionine, 3-methyllanthionine and other modified 
residues, such as dehydroalanine and dehydrobutyrine, none of which are known to exist in 
other proteins or peptides 22. Lanthionine and 3-methyllanthionine are synthesized in a two-
step mechanism where serine and threonine residues, respectively, are dehydrated and form 
thioether bonds with -SH groups in cysteine residues 23. The lantibiotics range in size from 
19 to 38 amino acids, and the percentage of residues involved in modifications are from 24% 
to 47% 24.  
 
The class I bacteriocins are further divided into type A and B, which are the elongated and 
globular peptides, respectively 25. The elongated type A peptides are amphipathic molecules 
with molecular masses ranging from 2164 Da to 3488 Da, and with two to seven net positive 
charges 11. These peptides kill target cells by permeabilizing their membranes by pore-
formation 25; 24; 26. The globular, smaller type B peptides have molecular masses from about 
1950 Da to 2050 Da, and have either a low net positive charge, no net charge or a net 
negative charge 11; 26. Their mode of action is inhibition of enzymatic activity 24; 26.   
 
 
1.3.2 Class II Bacteriocins 
The class II bacteriocins consist of peptides without modified residues 21. The class is 
further divided into three subclasses; subclass IIa, IIb and IIc. Within subclass IIa are the 
pediocin-like bacteriocins, which have antilisterial activity, and most share 40 to 60 % 
sequence similarity, including a highly conserved 14-residue motif in their N-terminal 
region, which also contains two conserved cysteins that form a disulfide bridge 27; 28. 
Subclass IIb contains the two-peptide bacteriocins, all of which consist of two different 
peptides, both of which must be present in equal molar amounts to obtain an optimal 
antimicrobial effect 29. The last subclass is IIc, which contains one-peptide bacteriocins that 
share no sequence-similarity to the pediocin-like bacteriocins 30.  
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1.3.3 Class III Bacteriocins 
The bacteriocins that belong to class III are probably the least studied class of the 
LAB bacteriocins. This class consist of large (>20 kDa), heat-labile antimicrobial proteins 11. 
1.4 Class IIb Bacteriocins 
About 15 class IIb two-peptide bacteriocins are known, and these are listed in Table 
1.1. This study deals with the class IIb two-peptide bacteriocin plantaricin EF, and the class 
IIb bacteriocins, and particularly plantaracin EF, will consequently be discussed in more 
detail. 
 
 
Table 1.1: Overview of genetically and biochemically characterized class IIb bacteriocins. 
 
 
 
 
Introduction     6 
1.4.1 Biosynthesis and Secretion of Class IIb Bacteriocins 
 For all two-peptide bacteriocins, the two structural genes encoding each of the two 
peptides are found next to each other in the same operon, which indicates that the two 
peptides are produced in approximately equal amounts 30; 31. In addition, the gene encoding 
the immunity protein is also found in the same operon as the bacteriocins’ structural genes 30. 
The immunity protein protects the bacteria from being killed by their own bacteriocin. 
Although it is unclear by what mechanism the immunity protein protects cells, it is suggested 
that it involves an interaction with membrane components 30. This interaction with 
membrane components is based on structure predictions of a number of putative immunity 
proteins of two-peptide bacteriocins, which all appear to contain transmembrane helices, 
such as the immunity proteins of thermophilin 13 32, plantaricin S 33, brochocin C 34, 
lactococcin MN 35, lactococcin G 36 and plantaricin EF and JK 31.  
 
The two peptides that constitute all two-peptide bacteriocins characterized so far are 
synthesized with a 15-30 residue double-glycine-type leader sequence at the N-terminal end 
19; 30. For transport of the bacteriocins out of cells, an ABC-transporter and an accessory-
protein are needed. The ABC-transporter resides in the membrane and cleaves of the N-
terminal leader-sequence as it transports the peptides to the outside 30. Studies involving the 
lactococcin G ABC transporter show that its N-terminal region contains the recognition- and 
cleavage-site for the lactococcin G leader-sequence, and that the leader is cleaved off at the 
C-terminal side of the double-glycine motif 37. Thus, the ABC transporter appears to exert 
proteolytic activity at the same time as it transports the bacteriocin out of cells. The exact 
role of the accessory protein is unclear, but it seems to be required for secretion of 
bacteriocins 28; 30. The genes encoding the ABC transporter and the accessory protein are in 
some cases found on the same operon as the bacteriocin structural genes and the gene 
encoding the immunity protein, as for lactococcin G 36, in other cases on a different, but 
nearby, operon, as for enterocin 1071 38; 39 and plantaricin EF and JK 31. 
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1.4.2 Regulation of the Biosynthesis of Class IIb Bacteriocins 
It has been evident for some years that bacteriocin production in Gram positive 
bacteria is, in some cases, regulated in a cell-density dependent manner, through a so-called 
three-component regulatory pathway (sometimes referred to as a two-component regulatory 
pathway) 19; 40 (Fig. 1.2). The genes encoding all three components are located on the same 
operon, and are simultaneously transcribed. The three components in this pathway are i) an 
induction factor, ii) a sensor histidine protein kinase and iii) a response regulator 19; 30; 40.  
 
The induction factor is a pheromone peptide, which is produced with an N-terminal double 
glycine-type leader, and is processed and secreted by the same ABC-transporter that 
transports bacteriocins out of cells 40. The synthesis of these pheromone peptides seems to be 
an autoregulatory process, where the production of the peptide itself is increased upon 
activation of the sensor histidine kinase 41; 40. 
 
The sensor histidine protein kinase is a membrane-bound protein that is activated upon 
binding of the peptide pheromone, which occurs when a certain threshold concentration of 
the peptide pheromone is attained 40. The activation of the kinase involves 
autophosphorylation of a conserved histidine residue in the cytoplasmic domain of the 
kinase. The phosphate-group is subsequently transferred to an aspartate residue in the 
receiver domain of the response regulator, which is a cytoplasmic protein. This leads to a 
conformational change in the response regulator, causing it, in most cases, to bind to specific 
regions of the target promoter, causing transcriptional activation of genes involved in the 
bacteriocin production and the transport of bacteriocins out of the cell 42; 40.  
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Fig. 1.2: Schematic overview of the three-component regulatory pathway that regulates biosynthesis 
of some two-peptide bacterocins (such as plantaricin EF) in Gram positive bacteria. Binding of the 
pheromone peptide to the membrane-bound histidine kinase leads to activation of the kinase, which again 
leads to activation and subsequent binding of a response regulator to the target promoter. After 
transcriptional activation of the bacteriocin operon, the bacteriocin is produced and transported out of the 
cell 40.   
 
1.4.3 Structure and Mode of Action of Class IIb Bacteriocins 
 Sequence analysis of class IIb bacteriocins shows that both peptides constituting the 
bacteriocins are cationic, and contain putative amphiphilic α-helices and/or hydrophobic 
regions 30. The net positive charge of the peptides presumably facilitates interaction with the 
negatively charged membrane of target cells, whereas the amphiphilic or hydrophobic 
segments facilitates penetration into the membrane 28. Structural studies by circular 
dichroism (CD) spectroscopy of some class IIb bacteriocins have shown that these peptides 
are unstructured and have low α-helical content in water, but achieve a higher α-helical 
content when exposed to more membrane-like environments, such as micelles and negatively 
charged liposomes. This has been shown to be the case for the two peptides (termed LcnG-α 
and LcnG-β) constituting the class IIb bacteriocin lactococcin G 43. It was also shown that 
increased α-helical structuring is obtained when LcnG-α and LcnG-β interact with each other 
in the presence of membrane-like entities, such as liposomes 43. This inter-peptide interaction 
and structuring presumably occurs when the peptides come in contact with the target 
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membrane, but before they get fully embedded in the membrane 44. By treating cells with 
one of the peptides followed by extensive washing, and then adding the complementary 
peptide, growth inhibition was observed. When mixing cells treated with one of the peptides 
with cells treated with the complementary peptide, no lactococcin G activity was found 45. 
This indicates that the individual peptides have the ability to interact stably with target 
membranes, but with no individual bactericidal effect, and that the peptides are not able to 
diffuse once bound to the membrane. When added to cells simultaneously, LcnG-α and 
LcnG-β show bactericidal effect at picomolar concentrations 29. A similar scenario is found 
for the two peptides constituting the two-peptide bacteriocin plantaricin JK 46; 47.  
 
Although the mode of action for class IIb bacteriocins is not entirely understood, two general 
mechanisms have been described; the “barrel-stave” model (Fig. 1.3), and the “carpet” 
model (Fig. 1.4) 48; 49. In the “barrel-stave” model (Fig. 1.3), the peptides associate and form 
trans-membrane pores, with the hydrophobic surfaces of the α-helices facing the 
hydrophobic core of the lipid bilayer, and the hydrophilic surfaces of the helices facing 
inwards, making an aqueous pore 49. According to the second model, the “carpet” model 
(Fig. 1.4), the peptides do not insert into the lipid bilayer, but rather bind onto the membrane 
of target cells, and cover it in a carpet-like manner. High local concentrations of peptides can 
lead to disruption of the membrane 49. There have been speculations about whether or not 
there is a target membrane-located receptor molecule involved in binding of two-peptide 
bacteriocins. This could be the basis for the different target cell specificity of these 
bacteriocins.   
 
After insertion into the membrane, the various bacteriocins show some specificity regarding 
which molecules they conduct across the membrane 30. Lactococcin G has been shown to 
make the target membrane permeable for potassium ions, but also other monovalent cations 
50, whereas plantaricin JK leads to anion-leakage in target cells 46; 47. In all cases, the 
consequences are detrimental for the target cells, as the proton motive force is destroyed.  
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Fig. 1.3: Illustration of the “barrel-stave” model for permeabilization of target membranes by 
antimicrobial peptides. The antimicrobial peptides adopt α-helical structures when they come in contact with 
a membrane-like environment (A), and the hydrophobic regions (marked in purple) interact with the membrane 
surface, while the hydrophilic regions (marked in blue) face the solvent (B). When a threshold concentration of 
peptides is reached, the peptides associate and form trans-membrane pores, with the hydrophobic surfaces 
facing outside, and the hydrophilic surfaces facing inwards, making an aqueous pore, which support leakage 
(C) 49.  
 
 
Fig. 1.4: Illustration of the “carpet” model for permeabilization of target membranes by antimicrobial 
peptides. The unstructured antimicrobial peptides form α-helices when they come in contact with a membrane-
like environment (A). The antimicrobial peptide binds to the membrane with the hydrophobic regions (blue) 
interacting with the phospholipid bilayer, and the hydrophilic part (blue) facing the solvent (B). A high local 
concentration of peptides leads to permeabilization of the membrane (C) 49.   
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1.4.4 Plantaricin EF 
Plantaricin EF is a two-peptide bacteriocin produced by the lactic acid bacteria 
Lactobacillus plantarum C11. The bacteriocin consists of the two peptides termed PlnE and 
PlnF. Indications of bacteriocin production by L. plantarum C11 were first reported in 1990 
51. Sequencing of the gene encoding the plantaricin-inducing factor plantaricin A (PlnA)1, 
plnA, together with its operon, plnABCD, was reported in 1993 52; 53. The first 
characterization of the PlnE and PlnF structural genes was reported in 1996, when four new 
PlnA-induced operons were identified by Northern blot and DNA sequencing 31; 40 (Fig. 1.5). 
Two of the PlnA-induced operons, plnEFI and plnJKLR, encode two two-peptide 
bacteriocins (plantaricin EF and plantaricin JK, respectively) and their cognate immunity 
proteins (plantaricin I and plantaricin L, respectively) 31; 54. A third PlnA-induced operon, 
plnMNOP, was by analogy to other operons that encode functional bacteriocins thought to 
encode a typical bacteriocin-like peptide (PlnN) and cognate immunity proteins (PlnM and 
PlnP) 31, but the mature PlnN peptide showed no bactericidal activity against indicator 
strains 54. A fourth PlnA-induced operon, plnGHSTUV, encodes an ABC transporter (PlnG) 
and an accessory protein (PlnH) that are involved in processing and transport of double-
glycine-leader type pre-peptides 31. 
 
 
Fig. 1.5: Genetic map of the 16,139 bp pln-locus in L. plantarum C11. Northern blot and DNA 
sequencing show 22 ORFs organized into the five PlnA-induced operons in Lactobacillus plantarum 
C11, including the plnABCD operon, which encodes PlnA 31. The plnJKLR operon encodes the two-
peptide bacteriocin plantaricin JK and the immunity protein PlnL. The plnMNOP operon encodes 
peptides with unknown function. The genes encoding the two-peptide bacteriocin plantaricin EF and 
its immunity protein PlnI, are in the plnEFI operon. Orf1 shows no similarity to other known proteins 
when homology searches are performed. 
 
 
                                                 
1 Plantaricin A is the peptide pheromone of the three component regulatory pathway that triggers the 
production of plantaricin EF. 
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Transcription of all five PlnA-induced operons2 in L. plantarum C11 has been shown to be 
activated during the exponential growth phase, and down-regulated before the stationary 
phase 55. All of the operons contain a -35 nucleotide region, and a preceding, conserved pair 
of direct repeats 31; 56, and it has been further demonstrated that these repeats serve as 
binding sites for both a transcriptional activator and a repressor, encoded by plnC and plnD, 
respectively 57; 58. This transcriptional regulation varies between the promoters, regarding 
both time and strength, even though all five promoters share an overall similarity 59.   
 
PlnE and PlnF are co-transcribed from the same operon, plnEFI, together with the cognate 
immunity protein, PlnI. The bacteriocins structural genes plnE and plnF encode two pre-
peptides, each with an N-terminal double-glycine leader type (Fig. 1.6) 31. 
 
PlnE:
MLQFEKLQYSRLPQKKLAKISGGFNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR
PlnF:
MKKFLVLRDRELNAISGGVFHAYSARGVRNNYKSAVGPADWVISAVRGFIHG
Fig. 1.6: Amino acid sequence of the PlnE and PlnF pre-peptides. The N-terminal leader sequence 
is shown in blue, with the two glycine-residues shown in green. The sequence of the mature peptide is 
shown in black, with glycine-residues in the GxxxG-motifs shown in red. 
 
Production of PlnE and PlnF, together with PlnA, PlnJ, PlnK and PlnN, were detected by 
amino acid sequencing and mass spectrometry in 1998 54. Amino acid sequencing showed 
that the mature PlnE consists of 33 amino acid residues, while the mature PlnF consist of 34 
amino acid residues. PlnE has a molecular mass of 3703 Da and isoelectric point of 12.1 
(mature peptide), while PlnF has a molecular mass of 3545 Da and isoelectric point of 10.7 
(mature peptide), as determined by amino acid sequencing and mass spectrometry 54; 31. 
 
The two peptides, PlnE and PlnF, have to be present in equal amounts to obtain optimal 
antibacterial activity. Although PlnF (but not PlnE) alone exerts some antimicrobial activity, 
the activity increases at least 103 times when the two peptides are combined 46; 54.  
                                                 
2 The five PlnA-induced operons are plnABCD, plnEFI, plnJKLR, plnMNOP and plnGHSTUV. 
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An Edmundson α-helical wheel display of their amino acid sequences (Fig. 1.7) shows that 
both peptides contain segments that can potentially form amphiphilic α-helical regions 54; 60.  
Fig. 1.7: The Edmundson α-helical wheel representation of PlnE and PlnF. Hydrophilic residues are 
colored black, and hydrophobic residues are colored white 54. Figure from Anderssen et al. 54. 
 
 
As mentioned previously (section 1.4.3), such amphiphilic regions are often associated with 
pore-forming toxins which insert themselves in cell membranes through a “barrel-stave”-
mechanism 48; 49. In fact, circular dichroism (CD) studies of PlnE and PlnF, both combined 
and individually, show that both peptides goes from being unstructured and having a low α-
helical content in aqueous solution, to adapting a mainly α-helical structure in the presence 
of more membrane-like environments, like trifluoroethanol (TFE) or dodecylphosphocholine 
(DPC) 46. CD measurements of the peptides in the presence of anionic 1,2-dioleoyl-sn-
glycero-3-[phosphor-rac-(1-glycerol)] (DOPG) liposomes show that premixing the peptides 
before adding the liposomes gives a higher calculated α-helical content than mixing 
liposomes containing one peptide with liposomes containing the complementary peptide 46. 
This suggests that formation of α-helices enables the PlnE and PlnF to interact with and 
permeabilize target membranes. 
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Mode of action studies reveal that plantaricin EF causes leakage of monovalent cations, 
namely protons (H+), rubidium (Rb+) and choline ions from target cells. The efflux of these 
cations causes dissipation of the trans-membrane pH gradient (∆pH) and the membrane 
potential (∆ψ), leading to inhibition of metabolism and subsequent growth inhibition 47.  
 
The three-dimensional structures of PlnE and PlnF in the presence of DPC-micelles were 
determined by NMR spectrometry in 2008 61 (Fig. 1.8 and 1.9, respectively). PlnE consists 
of two α-helical regions, one from residue 10 to 21, and the other from 25 to 31. Both helices 
are amphiphilic. The calculated structure of PlnF indicates an α-helical region stretching 
from residue 7 to 32, and around Pro20 the helix has a kink of 38±7 degrees, giving the helix 
more flexibility around this position. This α-helix has an amphiphilic C-terminal part, and a 
polar N-terminal part 61. 
 
 
Fig. 1.8: Cartoon-drawing of the three-dimensional structure of PlnE. The peptide contains two 
α-helical regions, from residue 10 to 21, and from residue 25 to 31. Figure from Fimland et al. 61. 
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Fig. 1.9: Cartoon-drawing of the three-dimensional structure of PlnF, which forms one α-
helical region from residue 7 to 32. Pro20 creates a kink in the helix. Figure from Fimland et 
al.  61. 
 
 
1.4.5 GxxxG Motifs 
GxxxG motifs consist of two glycine-residues separated by any three amino acid 
residues, a sequence shown by computational analysis to occur more frequently in trans-
membrane helices than is expected from a random occurrence 62; 63. If the GxxxG motif is 
found in an α-helix, the two glycine residues are approximately on the same side of the helix. 
The glycine residues may be substituted by other small amino acids, such as serine or 
alanine, and one may then speak of (small)xxx(small) motifs 64; 65. These motifs are known 
to stabilize helix-helix interaction in trans-membrane proteins, by providing a framework for 
dimerization 64. It is suggested that the glycine-residues affect the dimerization of α-helices 
by providing a surface for packaging of other amino acid residues at the interface, allowing 
for close helix proximity, which is the basis for van der Waals interactions between trans-
membrane helices 66. The occurrence of (small)xxx(small) motifs (where (small) can be 
glycine, alanine or serine) also minimizes steric hindrance of the helix backbone, because of 
the size of glycine, alanine and serine. This again is believed to enable Cα-H···O hydrogen 
bonds to form across the helix backbones, stabilizing the interaction between the helices 65; 
67. While the different GxxxG motifs confer α-helical interactions, the different motif 
sequence variants also promote specific associations, because of the topology of the interface 
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64. It has, for example, been shown that neither of PlnE nor PlnF functions together with 
either of the two peptides in the other two-peptide bacteriocins lactococcin G or plantaricin 
JK 54. 
 
Mutational studies 68; 69 and NMR-studies 70 of the peptides of the two-peptide bacteriocin 
lactococcin G suggest that the peptides interact through their GxxxG motifs in a parallel 
orientation and in a staggered fashion relative to each other 70.   
 
Both PlnE and PlnF contain GxxxG motifs. PlnE has two motifs, one from residue 5 to 9, 
and the other from residue 20 to 24. Only one GxxxG motif exists in PlnF, spanning from 
residue 30 to 34. It has not been determined how the two peptides interact, but the most 
likely pairing seems to be between the 20 to 24 residue GxxxG motif in PlnE and the 30 to 
34 residue motif in PlnF in a parallel orientation 61. It is also suggested that the interaction 
bringing the helices together may not be between both GxxxG motifs, but between a flat 
region (residue 16 to 20) in PlnF and the 20 to 24 residue GxxxG motif in PlnE, since it has 
been shown that GxxxG motifs alone do not confer helix dimerization 61; 71.  
 
 
1.4.6 Tyrosine and Tryptophan Residues 
Tyrosine (Tyr) and tryptophan (Trp) are aromatic residues that are prominent in trans-
membrane proteins, and especially in the interface regions of membranes. In fact, all trans-
membrane proteins with known three-dimensional structure share this preference for Tyr 
and, especially, Trp residues in these regions 72. The non-polar, aromatic side chains of Tyr 
and Trp tend to be buried within the hydrophobic part of the interface, and these two 
residues presumably enhance stability due to interface interactions with lipids 73; 74; 75; 76. 
Mutational analysis of Trp and Tyr in the two-peptide bacteriocin lactococcin G revealed a 
somewhat surprising tolerance for different residues replacing Trp and Tyr, suggesting that 
the C- and N-terminal ends of the lactococcin G peptides are flexible, and not embedded in a 
strict hydrophobic or hydrophilic environment 69.  
 
PlnF contains two Tyr residues, in position 5 and 14 (Y5 and Y14) and one Trp residue, in 
position 23 (W23, Fig. 1.6. bottom).   
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2. Aim of the Study 
Two-peptide bacteriocins consist of two different peptides which have to be present in 
equal molar amount to exert optimal antimicrobial effect. The peptides are thought to interact 
with each other through helix-helix interactions, and it is evident that many two-peptide 
bacteriocins contain one or more GxxxG motifs. One could therefore postulate that these 
GxxxG motifs are involved in the helix-helix interaction between complementary peptides. 
To investigate the importance of GxxxG motifs in the interaction between Plantaricin E 
(PlnE) and Plantaricin F (PlnF), mutational studies of GxxxG motifs in PlnF (and PlnE) are 
necessary. In addition, tyrosine and tryptophan residues are prominent in trans-membrane 
proteins, especially in the interface region. These residues are thought to interact with 
membrane-lipids, and thereby confer stability to the membrane-embedded protein. By 
performing mutational analysis of these GxxxG motifs and tyrosine and tryptophan residues, 
it is possible to gain insight into the structure-function relationship of PlnE and PlnF.  
 
The main aim of this study was to make a heterologous expression system for PlnF, using the 
two plasmids pSAK20 and a pLPV111-derivate. The pLPV111-derivate is constructed by 
connecting the gene encoding PlnF, plnF, and the gene encoding the immunity protein, plnI, 
to the leader-sequence of the bacteriocin sakacin P. pSAK20 contains all the genes necessary 
for production and transport of PlnF out of the cell. In wild type plantaricin EF-producers, 
PlnE and PlnF are produced in approximately equal amounts. Since PlnE and PlnF have 
similar biochemical properties, they are difficult to separate from each other based on these 
properties. The heterologous expression system makes it easier to purify the peptides, and to 
introduce point mutations.  
 
In order to assay the antimicrobial activity of mutant PlnF and wild type PlnE, and compare it 
to the activity of wild type plantaricin EF, the GxxxG motif and the tyrosine and tryptophan 
residues in PlnF were altered to other amino acid residues with different biochemical 
properties. This was done by in vitro site-directed mutagenesis. 
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3. Methods 
3.1 Gene Technological Methods 
3.1.1 Polymerase Chain Reaction (PCR) 
PCR is a method used for amplification of a DNA sequence without the use of living 
organisms 77. The principle behind PCR is the construction of two primers that anneal 
complementary to the ends of the desired sequence, which is then amplified in successive 
cycles by a heat-stable DNA polymerase, in a 5’ to 3’ direction (the amplified products are 
also used as templates in successive rounds of PCR). The result is several orders of magnitude 
amplification of DNA 77.  
 
Each PCR cycle consists of three steps: denaturation of DNA, annealing of primers, and 
elongation by a DNA polymerase. The time and temperature required for each step may vary, 
depending on several factors. The cycling is preceded by an initial step called “hot-start”, 
which denatures the DNA template, yielding single stranded DNA. A final elongation step is 
performed after the thermal cycling, to ensure complete elongation of newly synthesized PCR 
products. The number of cycles may vary. 
 
A typical PCR reaction mix requires several components. The template to be amplified may 
be several genes, a single gene, parts of a gene, or a non-coding region. Two oligonucleotide 
primers are designed, that anneal to the 3’ end and 5’ end of the DNA fragment to be 
amplified. In order to design the primers, the sequence at the end of the fragment, which is to 
be amplified, must be known. The four deoxynucleside triphosphates are the building blocks 
from which a new DNA strand is synthesized. Heat-stable DNA polymerases are responsible 
for the elongation of the new strand. A divalent cation is added to the reaction mix, which 
functions as a co-factor for the polymerase.  
 
The DNA polymerases used in this project were the Pfu DNA polymerase (Fermentas) and 
the Taq DNA polymerase (Fermentas). The Taq polymerase is less expensive than Pfu 
polymerase, but lacks 3’ to 5’ exonuclease proofreading activity. In addition it makes DNA 
products with 3’ adenine (A) overhangs. This makes the polymerase useful in TA-cloning, as 
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the products subsequently can be ligated into vectors with 3’ thymine (T) overhangs 78. The 
Pfu polymerase, on the other hand, has 3’ to 5’ proofreading activity, and therefore has a 
lower random mutation rate than Taq polymerase.  
 
PCR can be used in both the Megaprimer method 79 and for introduction of site-directed 
mutations in DNA, both of which were used in this thesis. The Megaprimer method was used 
to connect the sakacin P leader-sequence to the gene encoding PlnF. Point-mutations were 
constructed according to the protocol in The QuikChange® Site-Directed Mutagenesis kit 80. 
 
3.1.2 The Megaprimer Method 
This method is performed according to the principles described in Sambrook’s 
“Molecular cloning” 79. In this method, three oligonucleotide primers are used to perform two 
successive rounds of PCR. In the first round, two of the primers are used to synthesize a PCR 
product, which is used as a Megaprimer in the second round of PCR, together with a third 
oligonucleotide primer. The method is often used to connect a smaller DNA fragment to a 
bigger fragment.  
 
In this project, the method was used to connect the sakacin P leader sequence to the gene 
encoding PlnF (Fig. 3.1). The templates used were the plasmid pLT100α for the sakacin P 
leader-sequence amplification, and genomic DNA from L. plantarum C11 for amplification of 
the genes encoding PlnF and the immunity protein.   
 
In the first round of PCR (Fig. 3.1), the primers PlnFA and SakPB (see appendix 6.3.1 for 
sequences) was used to amplify the sakacin P leader sequence. PlnFA consists of two parts. 
One part anneals to the end of the leader-sequence in the first reaction, thus serving the 
primer-role. The other part does not anneal to the template (pLT100α), and exists as a non-
complementary “tail” in the first round, but anneals to the start of the PlnF gene in the 
template (L. plantarum C11 genomic DNA) in the second round of PCR. PlnEFimm was the 
other primer used in this round. After the two PCR rounds, a DNA fragment originating from 
two different templates is generated.  
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Fig. 3.1: Illustration of the connection of sakacin P leader-sequence to the genes encoding PlnF 
and PlnI by use of the Megaprimer method. The sakacin P leader-sequence is amplified in a first 
round of PCR with the primers PlnFA and SakPB. The template is the pLT100α plasmid. PlnFA consists 
of two parts; one part that is complementary and anneals to pLT100α, and a “tail” consisting of the start 
of plnF, which does not anneal to pLT100α. The PCR leads to the synthesis of a 334 bp megaprimer. In 
the second round of PCR, genomic DNA from L. plantarum C11 is used as template. The Megaprimer 
anneals to the start of the plnF-gene. The other primer, PlnEFimm, anneals to the end of the plnI-gene. 
After the second round of PCR, the final product is a 1437 bp fragment consisting of the sakacin P 
leader-sequence, and the genes encoding PlnF and PlnI.  
 
 
Reaction Conditions 
When the Pfu DNA polymerase was used in the first round of PCR, the reaction conditions 
were as suggested by the Pfu DNA polymerase protocol (Fermentas), and are listed below:  
 
1-5 μl DNA template (5-50 ng) 
1.25 μl 20 μM SakPB 
1.25 μl 20 μM PlnFA 
5 μl 10X Pfu buffer without MgSO4 
6 μl 3 mM MgSO4 
2 μl 5 mM dNTP (1.25 mM each) 
dH2O to a final volume of 50 μl 
1 μl 2.5 U/μl Pfu DNA Polymerase 
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Taq DNA polymerase (Fermentas) was used in the second round of PCR to create a final PCR 
product with 3’ A overhangs. This was done in order to sub-clone the final PCR product into 
a pGEM® T-Easy Vector, by the use of TA-cloning, for restriction digestion. The reason it 
was decided to use TA-cloning in this project will be explained more thoroughly in the 
results-section.  
  
The reaction mix for Taq DNA polymerase was the same as for Pfu polymerase, but with a 
few alterations, these being: 
 
1-5 μl DNA template (5-50 ng) 
1.25 μl megaprimer (50-200 ng) 
1.25 μl 20 μM PlnEFimm 
5 μl 10X Taq Polymerase buffer 
4 μl 25 mM MgCl2 
2 μl 5 mM dNTP (1.25 mM each) 
dH2O to a final volume of 50 μl 
0.5 μl 5 U/µl Taq DNA Polymerase 
 
After the initial “hot-start”, the DNA polymerase was added to the mix. This preceding step is 
necessary for inactivation of proteases and denaturation of the template DNA strands.  
 
The PCR was carried out using a PTC-200 Peltier Thermal cycler (MJ research), with the 
following program (Table 3.1): 
 
Table 3.1: Parameters for the PCR-program used in construction of the expression vector 
containing the genes coding for PlnF and PlnI. 
Segment Number of cycles Temperature Time
1 1 95 ºC                     Hot-start  7 min
2 30 95 ºC               Denaturation 45 sec
50 ºC                    Annealing 45 sec
72 ºC                   Elongation   2 min per 1 kb for Pfu
1 min per 2 kb for Taq
3 1 72 ºC          Final Elongation 10 min
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3.1.3 QuikChange® Site-Directed Mutagenesis 
General Information 
QuikChange® Site-Directed Mutagenesis is a four-step procedure (Fig. 3.2), and is 
used for introduction of point mutations, switching of amino acids, and deletion or insertion 
of amino acids residues 80. The method uses a double stranded DNA vector and two 
oligonucleotide primers containing the desired mutation. The primers are complementary to 
each other and to the double stranded template DNA. After denaturation of the vector DNA, 
the mutagenic primers anneal complementary to opposite strands of the vector. Elongation by 
Pfu DNA polymerase results in a mutated plasmid with staggered nicks. After the thermal 
cycling, the PCR product is treated with DpnI endonuclease. DpnI has the target sequence 5’-
Gm6ATC-3’, and is used to digest hemimethylated and methylated parental DNA, leaving the 
non-methylated, newly synthesized DNA intact for further use. After DpnI treatment, the 
plasmids are transformed into competent E. coli DH5α, where the cells DNA repair 
machinery seals the nick.  
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Fig. 3.2: An illustration of the four steps of the QuikChange® Site-Directed Mutagenesis 
protocol. In step one the plasmid is isolated for the mutagenesis reaction. Step two involves the 
mutagenic PCR. The third step is digestion of the template with DpnI, leaving only the mutated 
PCR products. The final step is transformation of the mutated plasmid. Figure from 
http://www.stratagene.com/manuals/200516.pdf (25.05.2009) 
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Reaction Conditions 
The sequences of the primers used to introduce the desired mutation into plnF are listed in 
section 6.3.2. 
All the work was carried out as suggested by the QuikChange® Site-Directed Mutagenesis 
protocol, but with small alterations to the reaction mix, which was as follows: 
 
1-5 μl DNA template (5-50 ng) 
1.25 μl forward primer (125 ng) 
1.25 μl reverse primer (125 ng) 
5 μl 10X Pfu buffer without MgSO4 
6 μl 3 mM MgSO4 
2 μl 5 mM dNTP (1.25 mM each) 
dH2O to a final volume of 50 μl 
1 μl 2.5 U/μl Pfu DNA polymerase 
 
The mutagenic PCR reactions were performed using a PTC-200 Peltier Thermal cycler (MJ 
research), with the following program (Table 3.2): 
 
Table 3.2: PCR parameters used for introducing point mutations. 
 
After the PCR, 1 µl of the 10 U/μl restriction enzyme DpnI (Fermentas) was added to the 
reaction mix, and incubated for 1 hr at 37 C.  
10 min72 ºC          Final Elongation13
11 min72 ºC                   Elongation
45 sec50 ºC                    Annealing                 
45 sec95 ºC               Denaturation 162
7 min95 ºC                      Hot-start11
TimeTemperatureNumber of cyclesSegment
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3.1.4 Plasmid and DNA Isolation 
Plasmids were isolated using the Nucleospin® Plasmid Kit from Machery-Nagel, 
according to the standard protocol. An additional step was added for plasmid isolation from 
Gram positive lactic acid bacteria. After resuspension of the cell pellet in the resuspension 
buffer A1, 15 μl 40 mg/ml lysozyme was added to the solution, and incubated at 37 ºC for 10-
15 min. The lysozyme degrades the cell walls in the Gram positive bacteria.  
 
Genomic DNA from L. plantarum C11 was isolated using the DNeasy® Tissue Kit 
(QIAGEN), according to the standard protocol for Gram positive bacteria. 
 
3.1.5 Agarose Gel Electrophoresis 
This method is used to separate DNA fragments based on their size 79. The purpose for 
this may be to purify PCR-products and restriction enzyme digests, and to control the size of 
PCR-products and plasmids. Agarose is a polysaccharide, which after boiling with Tris-
actetat-EDTA (TAE) buffer and subsequent cooling forms a porous matrix. The density of the 
matrix can be varied by using different concentrations of agarose. The DNA samples are 
added to wells in the gel. By applying an electrical field to the gel, the DNA, which is 
negatively charged at neutral pH, will migrate toward the positively charged catode. Ethidium 
bromide is added to the agarose before it forms a gel. The ethidium bromide is a DNA 
intercalating agent, which fluoresces orange when exposed to ultraviolet light.  
 
In this project, agarose (Sigma Aldrich) was added to 50 ml 1X TAE buffer (see appendix 
section 5.5) to a concentration of 1.0%, and sizing was done using either the 100 bp DNA 
Ladder Plus or the 1 kb DNA Ladder (Fermentas) as a standard, depending on the size of the 
DNA fragments to be separated. A Hoefer HE33 Mini Horizontal Submarine unit (Pharmacia 
Biotech-Amersham) was used together with an EPS600 (Pharmacia Biotech-Amersham) as a 
source of electricity. The electrophoresis conditions used were voltage of 70 V, electric 
current of 80 mA, and the gel was run for approximately 1 hr.  
 
For purification of the DNA bands from the TAE agarose gel, the “GFX™ PCR DNA and 
Gel Band Purification Kit” (GE Healthcare) was used. In the final elution step dH2O was used 
instead of the supplied elution buffer, and an elution volume of 50 µl was used.  
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3.1.6 Restriction Digestion and Vector Dephosphorylation 
Restriction digestion is performed using restriction enzymes. These enzymes are 
endonucleases isolated from bacteria and archaea that recognize specific DNA sequences, 
called restriction sites 79. The sites are between 4 and 8 nucleotides, and most often 
palindromic. The restriction sites are cleaved by the enzyme, giving rise to either “blunt 
ends”, which is when both strands are cut at the same place, or “sticky ends”, which is when 
the two strands are cut at different positions 79. When digesting two DNA fragments with the 
same restriction enzyme, identical cleavage sites at the end of the fragments are produced. If 
the two ends are “sticky” they can subsequently be ligated together by baseparing. Cut DNA 
fragments with “blunt ends” will ligate unspecifically with other “blunt end” DNA fragments.  
Restriction enzymes are grouped into three different types, but only type II is suitable for 
molecular cloning 81. Under the appropriate conditions, type II restriction enzymes are highly 
specific and will always cut at the same position within the restriction site. Type I and III, on 
the other hand, are not sequence specific enough to be used for cloning.  
 
Different enzymes function optimally in the buffer and buffer concentration specified by the 
producer. If a double digest is to be performed, a buffer which both enzymes function in 
should be used. The total amount of restriction enzyme in a digest should never be over 10% 
(v/v), since glycerol can inhibit the enzyme activity.  
 
Initially, the restriction enzymes ClaI and MluI (Promega) were used in this project for uni-
directional cloning, but after experiencing some trouble with digestion with ClaI, the 
restriction enzyme XbaI (Fermentas) was used instead. This will be discussed more 
thoroughly in the results-section. 
 
 
Reaction Conditions 
Restriction digests were carried out as suggested by the protocols given by Promega and 
Fermentas, but with slight alterations, this being the amount of plasmid or PCR product being 
used. ClaI (Promega) has 100% activity in buffer C, while MluI (Promega) has 100% activity 
in buffer D. XbaI (Fermentas) functions most optimally in 1X Buffer Tango™.  
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35-40 l 50-300 ng/l plasmid or PCR product 
5 l enzyme buffer (as specified by the producer) 
0.5 l 10 mg/ml acetylated BSA (for ClaI and MluI digestion) 
dH2O up to a total volume of 50 l 
1.5 l of each 10 U/l restriction enzyme 
 
The digestion mix was incubated for 2 hrs at 37 ºC.  
 
The restriction digested vector was dephosphorylated at its 5’ ends using Calf intestinal 
alkaline phosphatase (CIAP) (Fermentas). The removal of 5’ end phosphate-groups inhibits 
re-circularization and re-ligation of the vector. After addition of 1 µl of 1 U/µl CIAP, the 
digestion mix was incubated at 37 °C for 30 min. The enzyme was inactivated at 85 °C for 15 
min. 
  
3.1.7 Ligation 
Ligation of DNA fragments into vectors is performed by the use of DNA ligases. 
These enzymes have the ability to link together two double stranded DNA fragments with 
complementary “sticky ends” or “blunt ends”, by catalyzing the formation of covalent 5’- 3’ 
phosphodiester-bonds 79. ATP is required as a co-factor for the reaction.   
 
 
Reaction Conditions 
The ligation reactions were performed according to the T4 DNA Ligase protocol from 
Fermentas 82. Two ligation reactions were performed in this project. First, after unsuccessfully 
trying to ligate the digested PCR products into the plasmid pLPV111, the PCR product was 
ligated into the pGEM® T-Easy Vector by TA-cloning (Fig. 3.5). After digestion of the 
pGEM® T-Easy Vector containing the PCR product, the insert was ligated into the plasmid 
pLPV111, which was cut with the same restriction enzymes (Fig. 3.6)  The concentration of 
both vector and insert was measured with a Nanodrop ND-1000, and ligations in 3:1, 1:1 and 
1:3 insert to plasmid ratios were performed. 
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5-10 μl (50-400 ng) linear plasmid DNA 
Insert DNA in 3:1, 1:1 and 1:3 ratios to plasmid DNA 
2 μl 10X buffer for T4 DNA Ligase 
0.5 μl 10 mM ATP 
dH2O up to 20 μl total volum 
0.5 μl 5 U/μl T4 DNA Ligase 
 
The ligation reactions were incubated for 2 hrs at room temperature. 
 
The ligated product was an E. coli-Lactobacillus shuttle-vector, termed pPlnF100. 
 
3.1.8 DNA Sequencing 
The newly constructed plasmids were submitted to a sequencing service for 
sequencing by the chain-termination method of Sanger 83, in order to verify that the DNA 
sequence was correct.  
The sequencing in this project was done by the ABI-lab at CEES, using an ABI 3730 High-
throughput capillary electrophoresis sequencer. 
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3.1.9 Plasmids 
pSAK20 
pSAK20 (Fig. 3.4)  is a 11.2 kb pVS2-derived plasmid 84, and contains the genes 
necessary for transcription of the sakacin A structural gene, and the genes coding for the 
proteins needed to export and process pre-sakacin A. The genes coding for the structural gene 
of sakacin A and its immunity protein has been removed. The plasmid also contains a cassette 
for chloramphenicol-resistance (cat) 85.  
 
 
Fig. 3.4: Plasmid chart of pSAK20. cat 
is a marker for chloramphenicol-
resistance. orf4 encodes the sakacin A 
peptide pheromone, sapK encodes a 
histidine kinase, and sapR encodes a 
response regulator, together constituting 
a three-component regulatory system 30. 
sapT encodes an ABC transporter, and 
sapE encodes an accessory factor. Figure 
from Axelsson et al. 84. 
 
 
 
 
 
 
pGEM® T-Easy Vector  
pGEM® T-Easy Vector (Fig. 3.5) is a 3015 bp plasmid from Promega, which is 
prepared by EcoRV restriction digest and addition of 3’ terminal thymidine to both ends 86. 
This allows for higher efficiency of ligation of PCR products generated by DNA polymerases 
which add 3’-end single deoxyadenosines. The plasmid contains a marker for ampicillin-
resistance, and a lacZ-gene with a multiple cloning site (MCS) within the coding region of the 
β-galactosidase enzyme. This allows for blue-white selection. 
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Fig. 3.5: Plasmid chart of 
the pGEM® T-Easy 
Vector. Ampr is a marker 
for ampicillin resistance. 
The gene coding for the β-
galactosidase enzyme 
(lacZ) contains a polylinker 
region, allowing for blue-
white selection. Figure from 
Promega 86.  
 
 
 
pLPV111 
pLPV111 (Fig 3.6) is a pGEM-7Zf(+) (Promega) derivative plasmid. It is an E. coli-
Lactobacillus shuttle-vector, with a p256 replicon for replication in Lactobacillus, and a 
replication origo (ori) for replication in E. coli. The ampicillin-resistance gene has been 
replaced by the erythromycin-resistance gene (ermB) from the Lactobacillus reuteri-plasmid 
pLUL631. The lacZ-polylinker region comes from pGEM-7Zf(+).   
 
 
Fig. 3.6: Plasmid chart of the 
pLPV111 shuttle vector. The 
vector contains a marker for 
erythromycin restistance 
(ermB), and the gene encoding 
the β-galactosidase enzyme 
(lacZ), which enables blue-
white selection of colonies. 
Figure from Sørvig et al. 87. 
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pLT100 
 pLT100 is a pLPV111 derived plasmid constructed for expression of LcnG- and its 
cognate immunity protein, LcnGimm, and with the sakacin P leader-sequence (Fig. 3.7). The 
plasmid was constructed by ligating the sakacin P leader-sequence and the genes encoding 
LcnG- and the lactococcin G immunity protein into the shuttle-vector pLPV111. The 
plasmid contains the gene encoding erythromycin-resistance (ermB), and a replication origo 
for replication in both E. coli and Lactobacillus, ori and 256rep, respectively.   
 
 
Fig. 3.7: Plasmid chart of 
the pLPV111-derived 
plasmid pLT100.  The 
plasmid contains a marker for 
erythromycin-resistance 
(ermB), and the gene coding 
for LcnG-, one of the 
peptides constituting the two-
peptide bacteriocin 
Lactococcin G. In addition it 
contains the gene encoding 
the lactococcin G immunity 
protein. Figure adapted from 
Oppegård 88.  
 
 
 
 
 
3.1.10 Bacteriocin Expression 
3.1.10.1 Heterologous Bacteriocin Expression in Lactobacillus sake 
A system for heterologous expression of LAB bacteriocins class II has been described 
by Axelsson et al. 84. This system is based on the expression system of the class IIa pediocin-
like bacteriocin sakacin A. Two divergently described operons are needed for sakacin A 
production and transport out of the cell. One operon contains the sakacin A structural gene 
(sapA) and the structural gene encoding the immunity protein (saiA). The other operon 
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contains three genes encoding a three-component regulatory system necessary for 
transcriptional activation of the sakacin A structural gene and the immunity protein gene; 
orf4 encodes a peptide pheromone, sapK encodes a histidine kinase, and sapR, which 
encodes a response regulator. This operon also contains the gene coding for the ABC-
transporter, sapT, which is necessary for transport of sakacin A out of the cell, and an 
accessory factor, sapE. It has been shown that the two operons can be separated and placed 
on different plasmids, and still have transcription activation of the sakacin A promoter in 
trans 85; 84. By replacing the sakacin A structural gene and immunity protein gene with the 
gene encoding the bacteriocin of interest and its cognate immunity gene, and transforming 
them into a bacteriocin-deficient strain, it is possible to get an equal or higher production of 
the bacteriocin than in the wild type strains 84. 
 
The heterologous expression system was used in this project, with the plasmid pSAK20 (Fig. 
3.4) containing the orf4sapKRTE operon, and also a chloramphenicol-resistance cassette 
(cat). The other plasmid is a pLPV111-derivate, pPlnF100 (Fig. 3.3), containing the second 
operon, but with the sakacin A structural gene (sapA) and the gene encoding its cognate 
immunity protein (saiA) having been replaced by the PlnF structural gene (plnF) and the 
gene coding for its immunity protein (plnI). Both genes constitute an operon, and are placed 
under control of the sakacin A promoter. The plnF-gene encodes a precursor peptide with the 
N-terminal sakacin P leader sequence, which is cleaved off during transport out of the cell. It 
has been experimentally shown that the sakacin A leader-sequence and the sakacin P leader-
sequences are equally efficiently recognized and processed by the sakacin A ABC-
transporter 84. pLT100α contains the sakacin P leader-sequence, and was used as template in 
this project for construction of pPlnF100. Several bacteriocins with sakacin P leader-
sequences have previously been successfully produced and purified from cells expressing 
only the sakacin A ABC-transporter, including wild type and mutant lactococcin G and 
enterocin 1071 peptides 88. The plasmid, pPlnF100, also contains a marker gene coding for 
erythromycin-restistance (ermB). pPlnF100 is a shuttle vector that can be replicated in both 
E. coli and Lactobacillus. In this project, the plasmids were transformed into the bacteriocin-
deficient strain L. sake Lb790.  
 
Methods     34 
3.1.10.2 Bacterial Strains and Growth Conditions 
E. coli DH5α was used for plasmid cloning and isolation. The cells were grown in LB 
medium at 37 C at 225-250 rpm. Erythromycin was added to a final concentration of 150 
g/ml for selection (pPlnF100 contains the gene encoding erythromycin resistance). For 
selection of E. coli DH5α containing the pGEM® T-Easy Vector, 100 g/ml ampicillin was 
added to the medium. The medium was solidified by adding 1.5% agar (w/v) for cell growth 
on plates. E. coli DH5α was grown on LB-plates containing 150 g/ml erythromycin for 
selection pPlnF100, or 100 g/ml ampicillin for selection of pGEM® T-Easy Vector, and 
incubated at 37 C overnight. 
 
Lactobacillus sake Lb790/pSAK20 was used for bacteriocin production, and was grown in 
MRS medium at 30 C without agitation. Both chloramphenicol and erythromycin were 
added to a final concentration of 10 g/ml for selection (pPlnF100 contains the erythromycin 
resistance gene, and pSAK20 contains the chloramphenicol resistance cassette).  
For growth of L. sake Lb790/pSAK20/pPlnF100, MRS-plates containing 10 g/ml 
chloramphenicol and 10 g/ml erythromycin were used for selection of pSAK20 and 
pPlnF100, respectively. The cells were incubated at 30 C for 2 to 3 days.  
Lactobacillus plantarum C11 genomic DNA was used as a template in the second round of 
megaprimer PCR for amplification of the genes encoding PlnF and its immunity protein. The 
cells were grown in MRS medium at 30 C without agitation.   
Lactobacillus viridiscens NCDO 1655 (LMGT2314) was used as an indicator strain, and the 
cells were incubated in MRS and grown overnight at 30 C without agitation.  
 
 
3.1.11 Preparation of Competent Cells and Cell Transformation 
3.1.11.1 Preparation of Chemical Competent E. coli DH5-cells 
 
A 0.5 ml E. coli DH5 overnight culture was used to inoculate 25 ml of fresh LB-
medium, and incubated at 37 C (225-250 rpm) until the optical density at 600 nm reached 
0.3. The cells were then put on ice to stop growth, and immediately harvested by 
centrifugation at 5000 rpm and 4 C for 10 min in a JA-10 rotor (Beckman). After discarding 
the supernatant, the cell pellet was resuspended in 5 ml 0.1 M CaCl2 (4 C). After cooling the 
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cells on ice for 5 min, they were again centrifugated at 5000 rpm and 4 C for 10 min, and the 
supernatant was discarded. The cell pellet was resuspended in 1 ml 0.1 M CaCl2 (4 C) 
containing 10% (v/v) glycerol. After 15 min cooling on ice, the competent cells were divided 
into 100 l aliquots and stored at –80 C. 
 
3.1.11.2 Transformation of Competent E. coli DH5-cells 
The cells were transformed with pPlnF100 and the mutated plasmids according to the 
QuikChange® Site-Directed Mutagenesis protocol 80. After thawing the cells on ice, 1 l 
DpnI-treated DNA was added to the 50 l cell-aliquots. After 30 min incubation on ice, the 
transformation reaction was exposed to a 90 sec heat pulse (42 C) and 2 min incubation on 
ice. The cells were then transferred to 0.5 ml pre-heated (42 C) LB-medium, and cultured 
with agitation (225-250 rpm) at 37 C for 1 hr. Cell volumes of 100-200 l were then plated 
onto LB-plates containing 100 g/ml ampicillin when selecting for cells containing the 
pGEM® T-Easy Vector (Fig. 3.5), and 150 g/ml erythromycin when selecting for pPlnF100 
plasmids (Fig. 3.6).  
 
3.1.11.3 Preparation of Electrocompetent L. sake Lb790/pSAK20 
The cells were prepared basically according to the procedure suggested by Aukrust et 
al. 89: 
A 25 ml preculture of L. sake Lb790/pSAK20 was used to inoculate 100 ml fresh MRS 
medium containing 2.0-2.5% (w/v) glycine, to an OD600 of 0.1. Chloramphenicol was added 
to a final concentration of 10 g/ml for selective pressure. The culture was incubated at 30 C 
until an OD600 of 0.5-0.6 was reached, and the cells were then harvested by centrifugation at 
5000 rpm at 4 C for 7 min. The cells were resuspended in 100 ml ice cold 1 mM MgCl2, and 
pelleted by centrifugation at 5000 rpm at 4 C for 7 min. The supernatant was discarded, and 
the pellet was resuspended in 100 ml 30% (w/v) polyethylene glycol (PEG). The cells were 
once more pelleted by centrifugation, this time at 7000 rpm at 4 C for 10 min. The 
supernatant was discarded, and the cells were resuspended in 1 ml 30% (w/v) PEG, and used 
to make 50 l aliquots of competent cells.  
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3.1.11.4 Transformation of Electrocompetent L. sake Lb790/pSAK20 
After thawing the cells on ice, 2 l of plasmids were added to 50 l of competent L. 
sake Lb790/pSAK20 cells. The mix was then transferred to an ice cold electroporation cuvet 
(2 mm electrode gap). The electric pulse was delivered with voltage of 1.5 kV, capacitance of 
25 F and resistance of 400 . The time constant varied between 9.0 and 9.5 ms.  
Directly after electroporation, 1 ml of MRSSM (see appendix) was added to the cells, and 
transferred to a 1.5 ml microcentrifuge tube. The cells were incubated for 2 hrs at 30 C. 
Then, 100-200 l of the transformation mix were spread on MRS agar plates with 10 g/ml of 
chloramphenicol and 10 g/ml erythromycin. The MRS plates were incubated at 30 C for 2-
3 days. 
3.2 Bacteriocin Isolation and Purification 
3.2.1  Chromatography  
 Many procedures for isolation and purification of LAB bacteriocins exist, and most of 
them are based on the use of column chromatography or ammonium sulphate precipitation or 
combinations of these 90.  
Proteins are often isolated and purified by the use of column chromatography, as described in 
Sheehan’s “Physical Biochemistry: Principles and Applications” 91. The proteins are in a 
liquid mobile phase, which is passed through the chromatography column. The column 
contains a matrix of porous material, and is referred to as the stationary phase. Since different 
proteins have different properties, such as size, charge, hydrophobicity, and isoelectric point, 
the proteins can be separated on a column based on these characteristics. As the mixture 
passes through the stationary phase, the different proteins get retarded in the matrix, and will 
elute at different times.  
 
A simple two-step procedure for purification of pediocin-like bacteriocins and other cationic 
peptides has been developed by Uteng et al. 92.  
This procedure is based on two chromatography steps; the first being ion exchange 
chromatography, which separates peptides based on their net charge. The other step is reverse 
phase chromatography, which separates peptides based on their hydrophobic properties. 
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Isolation and purification of PlnF was performed basically according to the Uteng et al. 
procedure 92.  
 
3.2.1.1 Ion Exchange Chromatography  
An ion exchange chromatography column separates proteins based on their net charge, 
which can either be positive or negative. A column matrix with positively charged ligands 
will bind negatively charged peptides, and is called an anion exchange column. A column 
matrix with negatively charged ligands will bind positively charged proteins, and is called a 
cation exchange column 91. Since different proteins also have different net isoelectric points, it 
is possible to manipulate a proteins binding ability to the column by varying the pH. Proteins 
with the same charge as the column or no net charge will not bind. By increasing the salt 
concentration in the solvent that passes through the column, the proteins that bind to the 
column will be eluted.  
 
Since both PlnE and PlnF are positively charged at neutral pH, the cation exchanger SP-
Sepharose Fastflow from GE Healthcare was used. The SP-Sepharose Fastflow matrix has 
negatively charged sulfopropyl groups. 
 
 
Parameters 
A 10 ml overnight culture of bacteriocin-producing L. sake Lb790 cells grown at 30 ºC was 
added to 1 liter MRS medium, and grown to stationary phase. The cells were pelleted by 6000 
rpm for 10 min in a JA-10 rotor (Beckman). The supernatant was then applied to a cation 
exchange column, which contained 6 ml SP-Sepharose Fastflow (GE Healthcare) equilibrated 
with a 20 mM phosphate buffer (buffer A, pH~5.7). The column was then washed with 100 
ml buffer A to remove any unspecifically bound material. The bacteriocin was then eluted 
with 40 ml of a 20 mM phosphate buffer with 1 M NaCl (buffer B). Finally, 5 ml 2-propanol 
was added to the 40 ml bacteriocin fraction, and the mixture was sterile-filtrated through a 0.2 
μm filter. 
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3.2.1.2 Reverse Phase Chromatography  
As well as their characteristic surface charge, peptides also differ in respect to their net 
hydrophobicity. Most proteins will possess regions that are more or less hydrophobic. These 
regions will depend on the primary structure of the proteins.  
 
In reverse phase chromatography, according to Sheehan 91, hydrophobic groups have been 
immobilised on the stationary phase, while the proteins are added to the mobile phase, which 
is a polar solvent. When the mobile phase is added to the column, the proteins will bind to the 
stationary phase, due to hydrophobic interactions. By decreasing the polarity of the solvent, 
the peptides bound to the stationary phase will be eluted. Polar peptides will elute first, 
because of weak hydrophobic interactions. Non-polar peptides with stronger hydrophobic 
interactions will elute later.  
 
 
Parameters 
The reverse phase column used in this project was a Resource RPC column (3 ml) from GE 
Healthcare, consisting of polystyrene/divinylbenzene. It was connected to the Äkta system 
(GE Healthcare). The Äkta chromatography system was originally developed for protein 
purification, and is now widely used for preparative purposes of bioactive proteins. The 
system was used in this project for bacteriocin purification.  
 
Before running the sample the column was equilibrated with 5% 2-propanol containing 0.1% 
trifluoroacetic acid (TFA). The eluted bacteriocins from the cation exchange column were 
applied to the Resource RPC column on the Äkta system (GE Healthcare). The bacteriocin 
was eluted with a 15-60% linear gradient of 2-propanol with 0.1% TFA. Fractionation of 
eluate was based on UV absorption at 214 nm and 280 nm. The flowrate was 2.00 ml/min.   
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3.3 Quantification Methods 
3.3.1 Bacteriocin Activity Assay 
The bacteriocin activity of the unmodified PlnF together with synthetic PlnE was 
quantified using an 8 x 12 well ELISA microtiterplate-based system. First, 50 µl of MRS-
medium were added to all the wells. A total volume of 50 µl of PlnF (45 µl) and synthetic 
PlnE (5 µl) was then added to each well in the first column, so the total volume was 100 µl in 
all 8 wells in the first column. The MRS and bacteriocins were mixed by pipetting, and then 
50 µl was transferred over to the adjacent wells in the second column. The content in these 
wells were mixed again by pipetting, and 50 µl was transferred to the adjacent wells in the 
third column. This procedure was continued throughout the plate. After this serial-dilution, 
each column contained half the amount of bacteriocin as the wells in the previous column. 
The indicator strain used in this project was Lactobacillus viridescens NCDO 1655 
(LMGT2314). A stationary culture of L. viridescens NCDO 1655 was diluted 1:50-1:200 
before being added to the microtiter plates, 150 µl in each well. The plates were incubated at 
30 °C for 4-14 hours (depending on the dilution of the indicator strain). After incubation, 
growth inhibition of the L. viridescens NCDO 1655 was measured spectrophotometrically at 
600 nm with a microtiter plate reader (MR700 Microplate Reader, Dynatech). In those wells 
with a high bacteriocin-concentration the indicator-cells did not grow.  
 
3.3.2 MALDI-TOF Mass Spectrometry 
MALDI-TOF is a mass spectrometry method (Fig. 3.8), which enables accurate 
molecular weight determination of peptides and proteins in mixtures, and uses the principles 
described in “Physical Biochemistry: Principles and Applications” 91.  
MALDI stands for matrix-assisted laser desorption ionisation, and is a method used for 
ionisation. This method is based on bombarding the sample with pulses of high-energy UV 
radiation. The sample is held co-crystallized in a matrix, which has a lower concentration of 
the sample molecules than the matrix molecules. The purpose of the matrix is to separate the 
sample molecules, absorb the laser radiation which may otherwise break down the sample 
structure, and initiate ionisation of the sample. When the sample is exposed to the high-energy 
laser, the matrix and sample molecules are vaporised to gas-phase in a jet. In gas-phase, the 
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sample molecules get ionised by the excited matrix molecules, producing dominantly single-
charged ions, but also some multi-charged ions.     
MALDI uses a TOF (time-of-flight) analyser, which measures the time required for each ion 
to travel to the detector. This analyser accelerates the ions down a tube called the drift tube, 
which is free of magnetic field. The time required for each ion to travel through the drift tube 
and arrive at the detector is measured, and an m/z (mass to charge) value is calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8: Simplified scheme of MALDI-TOF mass spectrometry. The sample to be 
analysed is held co-crystallized in the matrix, which is bombarded with high-energy UV 
laser. This causes the sample-molecules and matrix-molecules to vaporise. The sample-
molecules get ionised by the matrix-molecules, and sample-ions are accelerated through 
the drift tube to the detector, where the time-of-flight is measured, and the m/z-ratio is 
determined.  
 
 
The identity of PlnF was verified by determination of the molecular mass using a MALDI-
TOF spectrometer. The work was performed by Morten Skaugen at the MS/Proteomics Core 
Facility at the Department of Chemistry and Biotechnology, Norwegian University of Life 
Sciences, Ås. 
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4.  Results 
4.1 Construction of pPlnF100 
A new expression plasmid, pPlnF100, was constructed for production of PlnF, and 
for easier construction and purification of PlnF-mutants. pPlnF100 is a derivate of the 
pLPV111 plasmid (section 3.1.9), and was constructed with an upstream sakacin P leader-
sequence, for heterologous expression together with the pSAK20 plasmid (section 3.1.9). 
The gene encoding the plantaricin EF immunity protein, plnI, was also introduced into 
pPlnF100, since it may be necessary for protection of the producer against PlnF. The genes 
encoding PlnF and PlnI were placed under the control of the sakacin A promoter.  
 
4.1.1 Synthesis of Insert by PCR 
Connection of the sakacin P leader-sequence to the DNA sequence coding for PlnF was 
done using the Megaprimer method (section 3.1.2). The ~350 bp PCR product (containing the 
sakacin P leader-sequence) from the first round of PCR (Fig. 4.1 A) was purified, and used as a 
Megaprimer in the second round of PCR, thereby connecting the sakacin P leader-sequence to 
the genes encoding PlnF and PlnI. The ~1450 bp product from the second round of PCR was 
likewise run on agarose gel for separation and verification, and purified (Fig. 4.1 B).  
 
 
Fig. 4.1: Separation and 
verification of PCR 
products by agarose gel 
electrophoresis. (A) The 
first round of PCR led to 
synthesis of a ~350 bp 
product. This product was 
subsequently used as a 
Megaprimer in the second 
round of PCR, which led 
to the synthesis of a ~1450 
bp product (B).   
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The purified ~1450 bp PCR product contained the sakacin P leader-sequence, the plnF-gene, 
the plnI-gene, and the restriction sites ClaI and MluI, as illustrated in Fig. 4.2.  
Sequencing of the PCR product confirmed the correct DNA sequence of the sakacin P 
leader-sequence, the plnF-gene, the plnI-gene, and the restriction sites.   
 
 
Final PCR product 
 
5’-acactttatgcttccggctcgtatgttgtgtggaattgtgagcggataacaatttca 
cacaggaaacagctatgaccatgattacgccaagctatttaggtgacactatagaatact
caagctatgcatccaacgcgtgaattcccctgtttaggaatgatttctgtaggcttcaag
aagttatgccacgtgatcaaagaaatcttgttatacttcactcgtacaaaaaataataac
agaggagattcttagttatggaaaagtttattgaattatctttaaaagaagtaacagcaa
ttacaggtggagttttccatgcctatagcgcgcgtggcgttcggaataattataaaagtg
ctgttgggcctgccgattgggtcattagcgctgtccgaggattcatccacggatagttca
agccatcaagtttaagcactataagaaagcactcgatttatgactgggcctgcagtgctc
agcctttttagtttatatggggggaattttaactatgccattaataaaagtaataatcac
agctatttactacctaatagtgctctttttaatgaatcctttgactgatattatgggaat
aaaagacggaccctttcaattcatattaactgaatctattatattaatcgcgataatcat
tctgaataggcgatatgttaagcaacctatccactggctacccgttaatatcatgtcaat
attaaagaagaatagtctgcctttgagcctagcaataatatttctacttattttctttcg
aaaccacatgtatcaatttttaatctcattattactttcgttgattgtagcgataactga
agaatacgcttttcgtggcatgatattcagaacgcttttagcactaaaccttaaaaattt
gccacattgcaggccaccatcgcttcgatgatgactgcttcgcttatttttgcggctatg
catttggtcaccttttatcacagcccgtatggtcagtattgtgtcagttctctatgttat
tgggttaggtattttacttgcagcaatctatttaaaaaccggaagcttactggctgccat
tagtgtccattggttgatagatttttctagtttctattctcaacgtattgacccaactca
atcacccattaacgggccaatggaagctcttctaaaggggctctttctaaatattttatt
cattggcattgctacgtttatcctatcctctaagcattggaagttattgagtatcctaaa
tattgaagataaaatagacgagtaatcatccattctgaattcctataaattattgtttgc
agcactacaatttcaattatctctgaagttttgggttacgctaagagctagtcatatcgc
taactaaatttcacgtcttaacgctatgctaatatacttacggatcgattactgtgc-3’ 
 
Fig. 4.2: The coding sequence of the final PCR product. The nucleotide sequence of the 
sakacin P leader-sequence (red) is followed by the nucleotide sequence of PlnF (blue) and PlnI 
(green). The MluI restriction site (5’-acgcgt-3’) is shown underlined in purple, and the ClaI 
restriction site (5’-atcgat-3’) is shown underlined in brown. The start-codon (atg) and stop-
codons (tag for plnF and taa for plnI, respectively) are shown in bold. The sakacin A promoter 
region is located between the MluI restriction site and the sakacin P leader-sequence.  
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4.1.2 Ligation of Insert Into pLPV111 
In order to ligate the ~1450 bp PCR product into the shuttle-vector pLPV111, the 
product was double-digested with the restriction enzymes ClaI and MluI in buffer D 
(Promega) according to the protocol. The restriction enzyme ClaI has 75-100% activity in 
buffer D, while MluI has 100% activity in the same buffer (according to the Promega 
protocol). The restriction site MluI is 133 bp from the 5’ terminal end on the PCR product, 
while the ClaI restriction site is 10 bp from the 3’ terminal end, as illustrated in Fig. 4.2, 
which in theory should result in a 1294 bp product after the double-digestion. The digestion 
reaction resulted in a 1300 bp product, which was separated and verified by agarose gel 
electrophoresis (Fig. 4.3 A), and subsequently purified from the gel.  
 
The pLPV111-derived plasmid pLT100α (Fig. 3.7) was also double-digested with the 
restriction enzymes ClaI and MluI in buffer D. This digestion reaction resulted in an 800 bp 
fragment being excised from pLT100α. The excised fragment was equivalent in size to the 
sakacin P leader-sequence, the gene encoding LcnG-, and the gene encoding the LcnG 
immunity protein, thereby resulting in the 4200 bp linearized pLPV111 plasmid (Fig. 4.3 
B).  
 
Fig. 4.3: Digestion reaction 
of the 1437 bp PCR product 
and the pLT100 plasmid 
with restriction enzymes ClaI 
and MluI. (A) Restriction 
digest of the final PCR 
products led to a ~1300 bp 
product. (B) Restriction digest 
of pLT100 led to an 800 bp 
fragment being excised, 
resulting in the 4200 bp 
linearized plasmid pLPV111. 
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Ligation reactions in 3:1, 1:1 and 1:3 ratios of insert to pLPV111 were performed, according 
to the T4 DNA Ligase (Fermentas) protocol (section 3.1.7). A volume of 1 l of each of the 
three reaction mixtures was transformed into E. coli DH5 according to the QuikChange® 
Site-Directed Mutagenesis protocol 80, and plated onto LB plates with erythromycin for 
selection of successfully transformed cells. The transformation resulted in several successful 
transformants, and single colonies were used to inoculate fresh LB medium containing 
erythromycin. The cultures were grown overnight before obtaining plasmids. Plasmids from 
each culture were sent to sequencing for verification of the pPlnF100 construct. Sequencing 
results showed that the linearized pLPV111 plasmid had re-ligated. pLPV111 should not be 
able re-ligate, because its ends had been cleaved with different restriction enzymes, thus 
resulting in non-complementary overhangs 79. In order to inhibit re-ligation of pLPV111, the 
linearized plasmid was treated with calf intestinal alkaline phosphatase (CIAP) (Fermentas) 
to remove the 5’ phosphate groups.  
 
After treatment of the linearized pLPV111 plasmid with CIAP, new ligation reactions in 3:1, 
1:1 and 1:3 insert to pLPV111 ratios were performed, and 1 l of each of the three reaction 
mixtures was transformed into E. coli DH5, and plated onto LB plates containing 
erythromycin for selection of successfully transformed cells. The transformation resulted in 
no successfully transformed cells. The positive control (E. coli DH5 transformed with 
pTL100) resulted in several colonies, while the negative control (competent E. coli DH5 
transformed without plasmid) gave no transformants. E. coli DH5 cells were transformed 
once more, this time with 4 l of the reactions mixtures, as suggested by the QuikChange® 
Site-Directed Mutagenesis protocol 80, and plated onto LB plates with erythromycin for 
selection of successfully transformed cells. No colonies were observed despite the increased 
amount of DNA used in the transformation. The positive control (E. coli DH5 transformed 
with pTL100) gave successful transformants.  
 
After the unsuccessful ligation reactions, it was decided to sub-clone the product into a 
pGEM® T-Easy Vector. This was done based on the fact that the ClaI restriction site is 
about 10 bp from the 3’-end of the final PCR product (see Fig. 4.2). Most restriction 
enzymes fail to cleave their recognition sequences if they are located near the end of DNA 
fragments, especially DNA fragments created by PCR 79. Failure to get the properly cut 
DNA insert may be the cause of the unsuccessful ligation reactions.  
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4.1.3 Sub-cloning of the PCR Product Into pGEM® T-Easy Vector 
Sub-cloning of the PCR product into a pGEM® T-Easy Vector was done using the 
principles of TA-cloning. In order to do this, the second round of PCR was performed again, 
using Taq DNA polymerase (Fermentas) instead of Pfu DNA polymerase, in order to create 
3’ end A-overhangs on the product. The 3’ A-overhangs will basepare with the 3’ T-
overhangs of the pGEM® T-Easy Vector, thereby ligating the PCR product into the vector. 
After running the second round of PCR with Taq DNA polymerase, ligation reactions in 3:1, 
1:1 and 1:3 insert to vector amounts were performed. In the first round of transformation into 
E. coli DH5 cells, 1 l of each of the three reaction mixtures was used. This resulted in no 
successful transformants. A second round of ligation reactions was performed, and this time 
the reactions were incubated at 4 ºC overnight. The reaction products were then transformed 
into E. coli DH5 cells, using 4 l instead of 1 l. This resulted in 3 colonies, which were 
used to inoculate overnight cultures from which plasmids were obtained (Fig. 4.4). The 
plasmids were sequenced for verification of the constructs, and the plasmid obtained from 
one of the three cultures had the correct construct, and was subsequently used further in this 
project.  
 
Fig. 4.4: Plasmid minipreps (1-3) 
from E. coli DH5 transformed 
with PCR product and pGEM® T-
Easy Vector ligation mixes. All 3 
minipreps contained isolated plasmid.  
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In order to obtain the DNA fragment of interest, the pGEM® T-Easy Vector construct (i.e. 
pGEM® T-Easy Vector with insert) was double-digested with restriction enzymes ClaI and 
MluI. The products of the digestion reaction were applied to an agarose gel for separation 
and verification of the excised fragment from the vector construct (Fig. 4.5). 
 
 
Fig. 4.5: (A) ClaI and MluI double-restriction digest of the 
pGEM® T-Easy Vector construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 1300 bp fragment (marked with obelix in Fig. 4.5) was purified from the gel, and 
ligation reactions in 3:1 and 1:1 insert to plasmid ratios were performed. The products of 
both ligation reactions were transformed into E. coli DH5, and plated onto LB plates 
containing erythromycin for selection of successfully transformed cells. The transformation 
resulted in no successful transformants, while the positive control (E. coli DH5α transformed 
with pLT100α) resulted in several colonies.  
The ligation efficiency was examined by performing PCR amplification over the putative 
insert with the pLPV111-specific primers SekF and SekR (Fig. 4.6 A). No products were 
amplified in the PCR reaction (Fig. 4.6 B), indicating that the ligation reaction was not 
successful.  
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Fig. 4.6: (A) Illustration of PCR amplification of ligation reactions with primer pairs SekF/SekR, 
AmpF/AmpR, SekF/AmpR and AmpF/SekR. If the ligations were successful, the PCR performed 
with AmpF/AmpR would result in amplification of the entire plasmid construct. PCR with SekF/SekR 
would result in a PCR product of ~1700 bp if the ligation had been successful. PCR with primer pairs 
SekF/AmpR and AmpF/SekR was also performed to further confirm if the ligation reactions had been 
successful. (B) PCR amplification of insert and pLPV111 3:1 and 1:1 ligation reactions with primer 
pairs SekF/SekR resulted in no product.  
 
 
After examining the polylinker region of pGEM® T-Easy Vector, it was found that the 
pGEM® T-Easy Vector contains a MluI restriction site in the polylinker region, 65 bp 
downstream of the ClaI restriction site in the insert (not shown on pGEM® T-Easy Vector 
chart, Fig. 3.5). This was in addition to the MluI restriction site in the insert. The double 
digestion of the pGEM® T-Easy Vector construct with MluI and ClaI in buffer D may have 
only resulted in cleavage of the MluI sites, and not the ClaI site. This again would have 
resulted in a 1350 bp fragment with MluI “sticky ends” in both ends, and may explain 
failure to ligate with the ClaI and MluI double digested pLPV111 plasmid.  
In order to ensure that the pGEM® T-Easy Vector construct was cleaved properly with ClaI, 
sequential digest of the plasmid was performed instead, starting with ClaI in buffer C (100% 
activity), which led to a linearization of the vector construct (Fig. 4.7 A). The linearized 
construct was purified, and followed by digestion with MluI in buffer D (Fig. 4.7 B), 
resulting in a 1300 bp fragment being cut out.  
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Fig. 4.7: Sequential restriction digest of the pGEM® T-Easy Vector construct with ClaI and 
MluI. (A) Restriction digest with ClaI of the pGEM® T-Easy Vector construct resulting in a 
linearized vector construct. (B) Subsequent restriction digest of the construct with MluI resulted in 
a 1300 bp fragment being excised.   
 
 
The ~1300 bp fragment was purified, and new 3:1 and 1:1 ligation reactions were performed 
with the insert and pLPV111. The products of the ligation reactions were transformed into E. 
coli DH5α, and plated onto LB plates with erythromycin for selection of successfully 
transformed cells. The transformation gave no successful transformants. Again, the positive 
control (E. coli DH5α transformed with pLT100α) gave several colonies.  
PCR amplification of the ligation reactions was performed with primers AmpF and AmpR 
(see section 6.3.1 for sequences). These two primers anneal to the same site in the insert, but 
on separate strands, resulting in forward synthesis by AmpF, and reverse synthesis by 
AmpR, giving amplification of plasmid with insert if the ligation reactions were successful. 
This would increase the concentration of possible ligation products, which again would 
increase transformation efficiency into E. coli DH5α. If the ligation reactions were 
unsuccessful, the PCR would result in no products (Fig. 4.6 A). PCR with primer pairs 
AmpF/SekR and SekF/AmpR were also performed.  
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Fig. 4.8: PCR amplification of pLPV111 and insert ligation 
reactions with primer pairs AmpF/AmpR (lane 1), 
SekF/AmpR (lane 2) and AmpF/SekR (lane 3). Only PCR 
amplification with primer pairs AmpF/SekR resulted in a 
product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR amplification with AmpF/AmpR resulted in no products. The amplification with 
AmpF/SekR resulted in a ~550 bp product, and amplification with SekF/AmpR resulted in 
no products (Fig 4.8), i.e. ligation over the MluI site seemed to have been successful, but not 
over the ClaI site.  
A more thorough examination of the sequence of the pGEM® T-Easy Vector construct 
revealed that the ClaI restriction site (5’-atcgat-3’) in the insert overlapped with a DNA 
adenine methylase (dam) site (5’-gatc-3’). The dam methylase attaches a methyl group to the 
N6 atom of the adenine in the recognition sequence 79, thereby preventing ClaI from cleaving 
in the same site. The first restriction digest with ClaI would then have been unsuccessful, 
leaving an intact plasmid or possibly unspecific cleaved plasmid, since the plasmid appear to 
have been linearized (Fig. 4.6 A), while the second restriction digest with MluI would cut at 
both MluI sites, excising a fragment ~65 bp longer than expected.  
This might be an explanation as to why the ligation reactions had been unsuccessful, and it 
was decided to change the ClaI restriction site into an XbaI restriction site (5’-tctaga-3’) by 
in vitro site-directed mutagenesis.  
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4.1.3 Mutagenesis of ClaI Restriction Site to XbaI Restriction Site 
The forward and the reverse mutagenic primers PlnEFXbaIF and PlnEFXbaIR, 
respectively (see section 6.3.1 for sequences), were used in PCR to introduce three point 
mutations in and adjacent to the ClaI restriction site in the pGEM® T-Easy Vector construct, 
creating an XbaI restriction site. After DpnI-treatment of the PCR products, 1 µl of the DNA 
was transformed into E. coli DH5α, and plated onto LB plates containing ampicillin for 
positive selection. Several colonies appeared on the plates, and some of the colonies were 
used to inoculate overnight cultures from which plasmids were isolated and purified. The 
XbaI restriction site introduced into the pGEM® T-Easy Vector construct was verified by 
DNA sequencing.  
The DNA fragment was amplified in vitro with PCR using primers SakP2 and Sp6 (see 
section 6.3.1 for sequences of primers), so as to obtain a higher concentration of the 
fragment (Fig. 4.9 A, lane 1). The ~1500 bp PCR product contained the sakacin P leader-
sequence, the plnF-gene, the plnI-gene, one XbaI restriction site, and two MluI restriction 
sites.  
 
The ~1500 bp PCR product was purified, then sequentially digested, first with XbaI, 
resulting in a ~1400 bp product (Fig. 4.9 B, lane 2). The product was purified, then cleaved 
with MluI for 6 hrs at room temperature, in order to ensure that the product was properly 
digested. The MluI digest resulted in a ~1300 bp PCR product (Fig. 4.9 C) with a MluI 
overhang at the 5’ end and an XbaI overhang at the 3’ end, as illustrated in Fig. 4.9 A.  
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Fig. 4.9: Sequential restriction digests of the fragment containing the sakacin P leader-
sequence, plnF-gene and plnI-gene. (A) Organization of the 1470 bp long amplified PCR 
product. (B) The ~1500 bp PCR product  (lane 1) was digested with XbaI (lane 2). (C) MluI 
digestion (6 hrs) of XbaI digested DNA resulted in a 1300 bp product.  
 
 
The plasmid pLT100α contains two XbaI restriction sites, and one MluI restriction site (Fig. 
4.10 A). One of the XbaI restriction sites in pLT100α is located in the polylinker region 
downstream of the gene encoding the lactococcin G immunity protein, the other site is 
located in the sequence coding for LcnG-α (Fig. 4.10 A). After an XbaI restriction digest, a 
~550 bp DNA fragment was excised from pLT100α (Fig. 4.10 B). MluI restriction digest of 
the remaining plasmid led to a ~250 bp fragment being excised, thus resulting in the ~4200 
bp linearized pLPV111 plasmid (Fig. 4.10 C, lane 3). 
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Fig. 4.10: Sequential restriction digest of pLT100α with XbaI and MluI. (A) Organization of 
XbaI and MluI restriction sites in pLT100α. (B) Restriction digest of pLT100α with XbaI resulted 
in a ~550 bp DNA fragment being excised. (C) Further restriction digest with MluI led to a ~250 
bp DNA fragment being excised (lane 3), resulting in the pLPV111 plasmid with a cleaved XbaI 
site at the 3’ end and a cleaved MluI site at the 5’ end. Undigested pLT100α plasmid in lane 1 and 
XbaI digested pLT100α in lane 2, for comparison.  
 
Ligation reactions of the insert and pLPV111 were performed in 3:1 and 1:1 ratios, and the 
products were transformed into E. coli DH5α, and plated onto LB plates containing 
erythromycin for selection of successfully transformed cells. The transformation gave no 
colonies. The positive control (E. coli DH5α transformed with pLT100α) resulted in 
colonies. PCR amplification over the two ligation sites was performed on the 3:1 ligation 
reaction to investigate if the insert was ligated into pLPV111 (Fig. 4.11 A). A ~1100 bp PCR 
product with primer pairs SekF/AmpR and a ~600 bp product with primer pairs AmpF/SekR 
would give an indication if the ligation reactions were successful. 
 
The PCR amplification results verified that the insert was ligated into pLVP111 (Fig. 4.11 
A), and it was decided to transform the ligation reactions into “XL-10 Gold® 
Ultracompetent Cells” (Stratagene) for higher transformation efficiency. The transformation 
was performed according to the “XL-10 Gold® Ultracompetent Cells” Protocol (Stratagene). 
The cells were plated onto LB plates containing erythromycin for selection of successfully 
transformed cells. The transformation resulted in 12 colonies, which were inoculated in fresh 
LB medium containing erythromycin. Of the 12 colonies, 8 had grown over the course of the 
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next day. These 8 cultures were minipreped, and each miniprep was run on agarose gel to 
verify the presence of a plasmid (Fig. 4.11 B).  
 
 
Fig. 4.11: (A) PCR amplification of the 3:1 ligation reaction with primers SekF and AmpR (lane 
1) and SekR and AmpF (lane 2) resulted in PCR products of ~1100 bp and ~600 bp, respectively. 
The size of the PCR products indicates that the ligation reaction had been successful. (B) Plasmid 
miniprep 1-8 from XL-10 Gold® Ultracompetent Cells transformed with ligation reactions.  
 
 
The plasmid minipreps showed that only one of the colonies contained a plasmid. The 
plasmid miniprep was sent to sequencing to verify the correct plasmid. Sequencing showed 
that the insert had been successfully ligated into pLPV111, but with two point mutations, 
one being upstream of the -35 box in the sakacin A promoter-region, the other being in the 
PlnI-encoding region, changing an isoleucine to a valine, which is a conservative mutation. 
The resulting plasmid is a 5.65 kB shuttle vector, termed pPlnF100 (Fig. 4.12). 
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Fig. 4.12: Plasmid chart of the pPlnF100 shuttle vector. ermB is a marker for erythromycin-resistance. 
sapAp is the sakacin A promoter, while plnF and plnI encodes PlnF and its cognate immunity protein, 
respectively. The plasmid contains replication origos for replication in both E. coli and Lactobacillus, ori and 
256rep, respectively.   
 
4.2 Purification and Analysis of PlnF 
After construction and verification of pPlnF100, the plasmid was transformed into 
the bacteriocin negative strain L. sake Lb790/pSAK20, as described in section 3.1.11.4. 
Selection of successfully transformed cells was performed on MRS-plates containing 
erythromycin and chloramphenicol. Single colonies were used to prepare -80 ºC stocks of 
the cell cultures.  
 
4.2.1 Cation Exchange Chromatography 
 A 10 ml pre-culture of L. sake Lb790/pSAK20/pPlnF100 was used to inoculate 1 liter 
of MRS as described in section 3.2.1.1. After incubation overnight at 30 ºC, the cell-culture 
was spun down, and the supernatant was applied to a cation-exchange chromatography 
column, and eluted with buffer B (20 mM phosphate buffer with 1 M NaCl, pH~5.7) (see 
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section 6.4). Sample volumes of 1 ml were taken from each step of the cation-exchange 
chromatography (i.e. supernatant, flow-through, wash and eluate).  
The obtained samples were tested in a bacteriocin activity assay combined with synthetic 
PlnE, using L. viridescens NCDO 1655 as an indicator strain (diluted 1:200 and grown for 
14 hrs). Synthetic PlnE was added in excess so that the purified PlnF was the limiting factor, 
and the antimicrobial activity was measured. This reflected the amount of purified PlnF in 
each step. Since synthetic PlnE was added to an excess, and PlnE alone has no activity, it 
was assumed that all of the purified PlnF was used, and on the basis of this assumption the 
degree of purified PlnF was calculated. Samples not combined with synthetic PlnE, and 
synthetic PlnE alone were used as negative controls, while synthetic PlnF combined with 
synthetic PlnE was used as positive control. None of samples alone nor synthetic PlnE alone 
gave any antimicrobial activity, whereas the combination of synthetic PlnF and synthetic 
PlnE gave growth inhibition in all the wells.  
 
Table 4.1 displays the purification fractions for PlnF using cation exchange chromatography. 
The table also summarizes the bacteriocin activity in the different fractions obtained 
combined with an excess of synthetic PlnE. 
 
Table 4.1: Purification of PlnF by the use of cation exchange chromatography. The bacteriocin was eluted 
from the cation exchange column with buffer B.  
Fraction Volume (ml) Bacteriocin Activity a) Yield (%)b) 
I    Culture Supernatant 1000 30 100 
II   Flow-through 1000 *nd *nd 
III  Wash (buffer A) 100 15 5 
IV  Eluate (buffer B) 40 15 2 
 
a) Bacteriocin activity is the fold dilution of the bacteriocin fraction that gives 50% growth inhibition of 
the indicator strain L. viridescens NCDO 1655. 
b) Yield is the bacteriocin activity in the fraction divided by the bacteriocin activity of the supernatant 
and multiplied by the fold volume reduction.  
* The abbreviation nd means that there was no detection of bacteriocin activity in the fraction.   
 
 
As shown in Table 4.1, the 1000 ml culture supernatant (fraction I) gave growth inhibition 
up to a 30-fold dilution, indicating a production of PlnF by L. sake 
Lb790/pSAK20/pPlnF100, although the production is low. The 1000 ml flowthrough 
fraction gave no growth inhibition of the indicator cells, and this implies that PlnF in the 
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supernatant had bound to the column material. The fraction obtained upon washing the 
cation exchange column with 100 ml buffer A (20 mM phosphate buffer, pH~5.7) gave 
growth inhibition up to a 15-fold dilution. This indicates that some PlnF was lost during the 
washing step. Fraction IV was the 40 ml eluted from the column with buffer B. This eluate 
gave growth inhibition up to a 15-fold dilution, which indicated elution of PlnF from the 
column, although in small amounts, as indicated by the 2% yield of PlnF. It was postulated 
that the bacteriocins bind so strongly to the cation exchange column, that they could not be 
eluted by using buffer B.  
 
In order to obtain more PlnF upon elution from the cation exchange column, it was decided 
to purify PlnF on a cation exchange column once more, this time using buffer B containing 6 
M guanidine hydrochloride (GuHCl). In addition to disrupting ionic interactions, GuHCl 
also disrupts hydrophobic interactions, such as protein aggregates, and might therefore give 
higher yield.  
The cation exchange chromatography was performed as before, this time eluting with buffer 
B containing 6 M GuHCl. Sample volumes of 1 ml were collected from each step in the 
chromatography of PlnF. Also, each of these fractions was combined with an excess of 
synthetic PlnE and tested in a bacteriocin activity assay. The control with synthetic PlnE 
alone gave no inhibition at all, and the control with synthetic PlnF combined with synthetic 
PlnE gave growth inhibition in all the wells. The results are summarized in Table 4.2. 
 
 
Table 4.2: Purification of PlnF by the use of cation exchange chromatography. The bacteriocin was eluted 
from the cation exchange column with buffer B containing 6 M GuHCl. 
Fraction Volume (ml) Bacteriocin Activity a) Yield (%)b) 
I    Culture Supernatant 1000 65 100 
II   Flow-through 1000 15 25 
III  Wash (buffer A) 100 10 1.3 
IV  Eluate (buffer B  
with 6 M GuHCl) 40 130 8 
 
a) Bacteriocin activity is the fold dilution of the bacteriocin fraction that gives 50% growth inhibition of 
the indicator strain L. viridescens NCDO 1655. 
b) Yield is the bacteriocin activity in the fraction divided by the bacteriocin activity of the supernatant 
and multiplied by the fold volume reduction. 
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As Table 4.2 shows, the 1000 ml culture supernatant combined with an excess of synthetic 
PlnE gave growth inhibition up to a 65-fold dilution. The supernatant alone gave growth 
inhibition up to a 15-fold dilution (not shown). This indicates production of PlnF by L. sake 
Lb790/pSAK20/pPlnF100. The 1000 ml flowthrough had bacteriocin activity up to a 15-fold 
dilution when combined with PlnE, the same as for the flowthrough alone (not shown). This 
might be due to antibiotics residuals in the media. The fraction obtained upon washing the 
column with buffer A gave growth inhibition up to a 10-fold dilution when combined with 
PlnE. No growth inhibition was observed when the wash-fraction was tested alone. This 
indicated that only minor amounts of PlnF were washed out with buffer A (1.3% PlnF was 
lost). The 40 ml fraction obtained when eluting PlnF with buffer B containing 6 M GuHCl 
gave growth inhibition up to a 130-fold dilution when combined with PlnE. These results 
indicates that PlnF was present in the eluate, but at a low concentration. By comparing 
Tables 4.1 and 4.2, it is evident that elution with buffer B containing 6 M GuHCl gives a 
higher yield of PlnF than elution with buffer B.  
 
4.2.2 Reverse Phase Chromatography 
The 40 ml eluate from the cation exchange column eluted with buffer B was added 5 
ml 2-propanol and applied to a reverse phase chromatography column. Several peaks were 
detected on the optical density profile upon linear elution with 2-propanol/0.1% TFA (Fig. 
4.13). The sample was fractionated after peaks obtained at 214 nm and 280 nm. PlnF was 
expected to elute between 30% and 50% 2-propanol, based on elution of other two-peptide 
bacteriocins, such as lactococcin G (LcnG-α and LcnG-β) 88.   
 
Results     58 
RPC PlnF
0
500
1000
1500
2000
2500
3000
3500
4000
0 10 20 30 40 50 60 70
ml
mAU
0
20
40
60
80
100
% conc
280nm
214nm
conc
 
Fig. 4.13: Chromatogram of PlnF obtained by reverse phase chromatography using the Äkta 
system. PlnF eluted at about 45% 2-propanol. The identity of the peptide was verified by bacteriocin 
activity assay, and by determining the mass with MALDI-TOF MS.  
 
Several of the fractions obtained were tested in bacteriocin activity assays combined with 
synthetic PlnE, using L. viridescens NCDO 1655 as an indicator strain (diluted 1:200 and 
grown for 14 hrs). Fractions not combined with synthetic PlnE, and an excess of synthetic 
PlnE alone were used as negative controls, and synthetic PlnF combined with synthetic PlnE 
was used as positive control. Synthetic PlnE alone gave no growth inhibition at all, while 
synthetic PlnF combined with synthetic PlnE gave growth inhibition in all wells. 
 
The fraction marked in Fig. 4.13 combined with an excess of synthetic PlnE gave growth 
inhibition up to a 500-fold dilution, while the fraction alone gave no growth inhibition. The 
fraction was analysed by mass spectrometry for verification of the presence of PlnF, and 
gave a mass of 3544 Da (Fig. 4.14), which is in good agreement with the theoretical mass of 
PlnF (3545 Da) 47. The peptide eluted at 45% 2-propanol in the reverse phase 
chromatography. 
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Fig. 4.14: Mass spectrum of PlnF. The peak of 3544 Da is in good consistence with PlnF’s theoretical mass; 
3545 Da. 
 
Because of the low activity in the supernatant, it was postulated that the positively charged 
bacteriocins might bind to the negatively charged membrane surface of the producer cell, as 
has been shown to be the case for plantaricin C19 93. In order to investigate this, the pelleted 
cells were resuspended in 1 M NaCl. High salt concentration will disrupt any electrostatic 
interactions between the bacteriocins and cell membranes. The resuspended cells were 
pelleted once more, and the culture supernatant from the cells was tested for bacteriocin 
activity by combining it with an excess of synthetic PlnE. The indicator strain used was L. 
viridescens NCDO 1655 (diluted 1:200 and grown for 14 hrs). The supernatant not 
combined with synthetic PlnE, synthetic PlnE alone, and 1 M NaCl were used as negative 
controls. Synthetic PlnE combined with synthetic PlnF was used as positive control.   
 
The culture supernatant from the cells resuspended in NaCl gave no growth inhibition. 
Neither of the negative controls gave growth inhibition, while the positive control gave 
growth inhibition in all wells. These results indicate that PlnF most likely does not bind to 
the membrane of the producer cells.  
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4.3 Construction of PlnF Mutants 
To study the importance of GxxxG motifs in helix-helix interaction between 
the two complementary peptides of plantaricin EF, point mutations were introduced in the 
GxxxG motif in PlnF. Fig. 4.15 displays the nucleotide and amino acid sequences of PlnF. 
The glycine residues in the GxxxG motif are marked in green. Both glycines in the motif 
were exchanged with leucine, serine, alanine, lysine and glutamine. 
Similarly, in order to examine to what extent tyrosine and tryptophan residues affect the 
stability of PlnF in the membrane, its two tyrosine residues were exchanged with tryptophan, 
arginine, leucine and phenylalanine, and the tryptophan residue was exchanged with 
tyrosine, arginine, leucine and phenylalanine. The two tyrosine residues are marked in blue, 
and the tryptophan residue in red, in Fig. 4.15.  
 
 
PlnF 
 
atggaaaagtttattgaattatctttaaaagaagtaacagcaattacaggtgga| 
M  E  K  F  I  E  L  S  L  K  E  V  T  A  I  T  G  G 
    5              14        23 
gttttccatgcctatagcgcgcgtggcgttcggaataattataaaagtgctgttgggcctgccgattgggtcatt
V  F  H  A  Y  S  A  R  G  V  R  N  N  Y  K  S  A  V  G  P  A  D  W  V  I   
   30   34 
agcgctgtccgaggattcatccacgga|tagttcaagccatcaagt 
S  A  V  R  G  F  I  H  G   STOP 
 
Fig. 4.15: Nucleotide sequence and amino acid sequence of the N-terminal sakacin P leader-sequence (first 
row) followed by the nucleotide sequence and amino acid sequence of the mature PlnF. The GxxxG motif 
ranges from residue 30 to 34 (green), the tyrosine residues are in position 5 and 14 (blue), and the tryptophan 
residue is in position 23 (red).   
 
 
The mutants were termed according to the amino acid residue that has been exchanged, 
followed by the new amino acid residue. If for instance the glycine residue in position 30 
was exchanged with an alanine, the mutant was termed G30A.  
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A total of 21 mutants were constructed by the use of in vitro site-directed mutagenesis, and 
verified by DNA sequencing, as described in section 3.1.3 (Table 4.3). The mutations were 
introduced by PCR, by the use of forward and reverse mutagenic primers. The names and 
sequences of these primers are listed in section 5.4.2. DpnI was used to digest methylated, 
parental DNA and to screen for unmethylated, newly synthesized DNA containing the 
mutations. The DpnI-treated DNA was then used to transform E. coli DH5α, and the 
successfully transformed cells were selected on LB plates containing erythromycin. Single 
colonies of the transformed cells were used to inoculate overnight cultures. The cultures 
were subsequently plasmid minipreped, and the minipreps were sequenced for verification of 
the desired mutations. All 21 mutants were verified by DNA sequencing (results not shown).  
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Table 4.3: Construction, transformation and verification of pPlnF100 mutants. 
 
*- indicates that the mutant plasmid has not been verified by DNA sequencing.
   PCR Products PCR Products Plasmid Isolation and 
Mutants Observed on Gel Transformed Into E. coli DH5α Verification by Sequencing
GxxxG Motif         
G30L +  +  + 
G30S +  +  + 
G30A +  +  + 
G30K +  +  + 
G30Q +  +  + 
G34L +  +  + 
G34S +  +  + 
G34A +  +  + 
G34K +  +  + 
G34Q +  +  + 
Tryptophan Residue         
W23Y +  +  + 
W23R +  +  + 
W23L +  +  + 
W23F +  +  + 
Tyrosine Residues         
Y5W +  +  + 
Y5R +  +  + 
Y5L +  +  + 
Y5F +  +  + 
Y14W +  +  *‐ 
Y14R +  +  + 
Y14L +  +  + 
Y14F +  +  + 
Number of Mutants  22 22 21 
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5. Discussion 
Most of the time used for this project was spent constructing the pPlnF100 plasmid 
for heterologous expression of PlnF and its mutants. The pPlnF100 plasmid contains the 
sakacin P leader-sequence and the genes encoding PlnF and its immunity protein. This 
expression system allows for individual and increased expression of both the bacteriocin and 
its mutants, as opposed to what would be the case in the natural producer of PlnF, 
Lactobacillus plantarum C11. This again will make it easier to purify and isolate the mutant 
peptides. The peptides will subsequently be used in structure-function analysis of plantaricin 
EF, and to gain insight into the importance of the GxxxG motif and the tryptophan and 
tyrosine residues.  
 
5.1 Construction of pPlnF100 
There were some obstacles associated with the construction of pPlnF100, mainly due 
to the restriction digests and subsequent ligation reactions. These obstacles were overcome 
by modifying some of the methods used for construction of the pPlnF100 plasmid, as 
described in section 4.1. After sub-cloning of the PCR product into the pGEM® T-Easy 
Vector, changing the ClaI restriction site in the PCR product into an XbaI restriction site, 
and performing sequential digest of the pGEM® T-Easy Vector construct with XbaI and 
MluI, the insert was successfully ligated into pLPV111, thereby completing the construction 
of the pPlnF100 plasmid. As mentioned in section 4.1, the plasmid contains two point 
mutations, one upstream of the -35 box in the sakacin A promoter-region, the other in the 
PlnI-encoding region, changing an isoleucine to a valine. Since none of these mutations are 
located in the plnF-gene, and the mutation located in the plnI-gene is a conservative 
mutation, it was decided to use the pPlnF100 plasmid with the mutations further in this 
project.   
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5.2 Purification of PlnF 
pPlnF100 was transformed into L. sake Lb790/pSAK20 for production of PlnF, as 
described in section 4.2. The bacteriocin was subsequently purified and isolated using cation 
exchange chromatography and reverse phase chromatography, and its identity was verified 
using mass spectrometry and bacteriocin activity assay.  
 
The bacteriocin activity in the culture supernatant in combination with synthetic PlnE 
indicated production of PlnF, although a low production. If the problem with low yield of 
PlnF is due to low production, this will most likely propagate to the production of the 
mutants as well, which might cause problems with their purification and quantification. It 
was postulated that the low production of PlnF might be a result of either of the two point 
mutations in pPlnF100. The point mutation in the immunity protein could possibly have 
been so deleterious that the protein could no longer serve its function to the producer cell, 
thereby resulting in the cell being killed by its own bacteriocin and not being able to produce 
PlnF. However, cultures of the producer cells L. sake Lb790/pSAK20/pPlnF100 were grown 
to the stationary phase, so the mutation is most likely neutral (as expected considering the 
fact that the mutation is conservative; changing an isoleucine to a valine), maintaining the 
function of the immunity protein. The mutation upstream of the sakacin A promoter region 
might result in down-regulation of transcription of PlnF. Although the mutation is not 
located in the core promoter (i.e. the -10 box or the -35 box), the mutation is situated in the   
-59 to -38 region, a region known as the UP (upstream) element. This element increases 
promoter activity when located upstream of the -35 box 94, and the mutation upstream of the 
sakacin A promoter might therefore be a possible reason for the low production of PlnF. 
PlnF was produced with a sakacin P leader-sequence in order for the sakacin A ABC-
transporter to recognize and transport the peptide out of the cell. Even though the ABC-
transporter recognizes and transports peptides with sakacin A leader-sequences, it has been 
experimentally shown that the ABC-transporter also recognizes peptides with sakacin P 
leader-sequences 84. This has indeed been shown to be the case for both LcnG-α and LcnG-β 
88. The sakacin A leader-sequence and the sakacin P leader-sequence share ~50% amino acid 
sequence identity (refer to Mathiesen et al. for sequences 95), and this is evidently similar 
enough for the ABC-transporter to recognize the sakacin P leader-sequence 88. One might, 
however, speculate that the amino acid composition of the bacteriocin itself plays a part in 
the recognition and transport by the sakacin A ABC-transporter. It is known that production 
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of various bacteriocins with identical sakacin P leader sequence vary considerably. A 
heterologous expression system identical to the one used in this project was constructed for 
production of each of the two peptides PlnJ and PlnK, which constitute the two-peptide 
bacteriocin plantaricin JK. The genes encoding PlnJ and PlnK are preceded by a sakacin A 
promoter, and the peptides are synthesized with a sakacin P leader-sequence. Attempts to 
purify and isolate the two individually expressed peptides have been performed, but both 
peptides seem to be expressed at a low level, making their isolation difficult (personal 
conversations with C. Oppegård and P.Rogne).  
 
Although the production of PlnF seemed to be quite low, optimalization of the purification 
procedure is needed, as indicated by the low yield from the cation exchange chromatography 
(Tables 4.1 and 4.2). When testing the activity of the buffer B eluate from the cation 
exchange column, only a 2% yield was obtained (Table 4.1). The activity obtained upon 
eluting the column with buffer B containing 6 M GuHCl resulted in 8% yield (Table 4.2). It 
is apparent that elution of the column with 6 M GuHCl gives a higher yield of PlnF than 
elution with buffer B alone, but 8% yield is still lower than would be expected, as compared 
to purification of other bacteriocins, such as LcnG-α and LcnG-β 88. If the bacteriocin had 
not bound to the column when applying the culture supernatant, a high yield would have 
been detected in the flowthrough. Similarly, if PlnF had been washed out from the column 
with buffer A, a high yield would have been detected in the wash-fraction. This was not the 
case for either of the purification steps (as given in Tables 4.1 and 4.2). This indicated that 
PlnF was bound so strongly to the column that neither buffer B nor 6 M GuHCl were able to 
elute the bacteriocin. Because the problem in the purification step of PlnF apparently is 
associated with the cation exchange chromatography, possible solutions might be to use 
stronger elution buffers or different ligands in the cation exchange column, or possibly a 
different purification step altogether. Purification of the class IIa pediocin-like bacteriocin 
enterocin P has proven to be somewhat difficult, as the peptide seems to bind irreversibly to 
all tested column material (personal conversation with H. S. Haugen). 
The fraction obtained from the reverse phase column resulted in growth inhibition up to a 
500-fold dilution (section 4.2.2), giving a 1.6% yield. However, because the eluate applied 
onto the reverse phase column gave a 2% yield (Table 4.1), only about ~20% of PlnF in the 
eluate from the cation exchange column was lost during reverse phase chromatography.  
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5.3 Constructions of the Mutants 
Constructions of the mutant versions of pPlnF100 went according to the protocol, and 
all the mutated versions were obtained, except for Y14W.  
 
The residues chosen for substitution of the glycines in the GxxxG motif were serine, alanine, 
leucine, lysine and glutamine. The reason for choosing serine and alanine was that both these 
residues are small, and substitution of the glycines with any of these will most likely not 
affect helix-helix interaction with PlnE. Leucine was chosen because it is a large, 
hydrophobic residue and lysine and glutamine were chosen because they are large, 
hydrophilic residues. Substitution of the glycine residues with any of these three large 
residues is expected to be detrimental to the helix-helix interaction between PlnE and PlnF, 
resulting in inactivation of plantaricin EF. By replacing  the glycine residues with both large 
hydrophobic and large hydrophilic residues, one might also gain insight into if the 
hydrophobicity of the residues in these positions are of significance.  
The tryptophan and tyrosine residues in PlnF presumably enhance stability due to membrane 
interface interactions with lipids in the target membrane. In order to investigate this, it was 
decided to substitute the tryptophan residue with tyrosine, phenylalanine, arginine and 
leucine residues. Tyrosine and phenylalanine are aromatic residues, and substitution of 
tryptophan with either of these residues is believed to not affect the positioning of the 
peptide in the membrane. Arginine is a positively charged, hydrophilic residue, which is 
thought to position itself in the more hydrophilic membrane surface. Leucine, on the other 
hand, is a hydrophobic residue, and is thought to position itself in the more hydrophobic 
interior of the membrane. Substitution of tryptophan with any of these two residues will 
most likely affect the positioning of PlnF in the membrane. Likewise, by substituting the 
aromatic tyrosines with either of the two other aromatic residues tryptophan and 
phenylalanine, the positioning of PlnF in the membrane will not be affected. By changing the 
tyrosines with either leucine (hydrophobic residue) or arginine (hydrophilic residue), it is 
believed that these residues will interact either with the interior or the exterior of the 
membrane, respectively.    
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 5.4 Future Aspects 
On the basis of the pPlnF100 plasmid and its mutant versions constructed in this 
project, structure-function analysis of PlnF can now be performed. The analysis may give 
further insight into the importance of GxxxG motifs and tryptophan and tyrosine residues in 
plantaricin EF.  
 
Another future aspect is, as previously mentioned, optimalization of the purification 
procedure of PlnF. A higher yield of PlnF may be obtained by altering one or several of the 
parameters in the cation exchange chromatography, or by using other purification methods 
altogether.  
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6 Appendix 
6.1 Abbreviations 
 
ABC  ATP-binding cassette 
CD  circular dichroism  
DNA  deoxyribonucleic acid 
DOPG  1,2-dioleoyl-sn-glycero-3-[phosphor-rac-(1-glycerol)] 
DPC  dodecylphosphocholine 
E. coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
L. sake  Lactobacillus sake 
LAB  lactic acid bacteria 
LB  Luria-Bertani 
LcnG  lactococcin G 
LMGT  Laboratory of Microbial Gene Technology 
MALDI matrix-assisted laser desorbtion ionization 
MCS  multiple cloning site 
MRS  de Man-Rogosa-Sharpe 
MS  mass spectrometry 
NCDO  National Collection of Dairy Organisms 
NMR  nuclear magnetic resonance 
OD  optical density 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
PlnE  plantaricin E 
PlnF  plantaricin F 
PlnI  plantaricin I 
PlnJ  plantaricin J 
PlnK  plantaricin K 
TFA  trifluoroacetic acid 
TFE  trifluoroethanol 
TOF  time-of-flight 
UV  ultra violet 
(v/v)  (volume/volume) 
(w/v)  (weight/volume) 
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Single and Three Letter Abbreviation for the Amino Acids 
 
A Ala Alanine 
C Cys Cysteine 
D Asp Aspartic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I Ile Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gln Glutamine 
R Arg Arginine 
S Ser Serine 
T Thr Threonine 
V Val Valine 
W Trp Tryptophan 
Y Tyr Tyrosine 
 
 
 
Abbreviations for the Triphosphate Nucleotides 
 
(d)ATP (deoxy) adenosine triphosphate 
(d)CTP (deoxy) cytidine triphosphate 
(d)GTP (deoxy) guanosine triphosphate 
dTTP  deoxythymidine triphosphate 
UTP  uridine triphosphate 
dNTP  deoxynucleotid triphosphate 
 
 
 
Single letter abbreviations for the Bases 
 
A Adenine 
C Cytosine 
G Guanine 
T Thymine 
U Uracil 
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6.2 Chemicals and Equipment 
 
 
Chemicals       Manufacturer 
 
Agar        Merck 
 
Agarose       Merck 
 
Ampicillin       CALBIOCHEM 
 
100 bp DNA ladder plus     Fermentas 
 
CaCl2        Merck 
 
Chloramphenicol      Sigma 
 
dNTPs (dATP, dCTP, dGTP, dTTP)    Amersham Biosciences 
 
Dpn I restriction enzyme     New England Biolabs 
 
Erythromycin       Sigma 
 
Ethidium bromide      Amersham Biosciences 
 
Ethylenediaminetetraacetic acid (EDTA)   Sigma 
 
Glucose       Sigma 
 
Glycerol       VWR 
 
Glycine       Sigma 
 
1 kb DNA ladder      Fermentas 
 
6xLoading Dye Solution     Fermentas 
 
MgCl2        AppliChem    
 
MRS broth       OXOID 
 
Mutagenic primers      Eurogentec S.A. 
 
M17 broth       OXOID 
 
NaCl        VWR 
 
NaH2PO4       J. T. Baker 
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Na2HPO4       Merck    
    
Peptone       Merck 
 
Pfu DNA polymerase buffer     Fermentas 
 
Pfu DNA polymerase      Fermentas    
 
Polyethylene glycol (PEG)     Merck 
 
2-propanol       Merck 
 
SakP2 (endprimer)      GIBCO BRL 
 
SakPC (sequencing primer)     GIBCO BRL 
 
SP-Sepharose Fast Flow     GE Healthcare 
 
Taq DNA polymerase buffer     Fermentas 
 
Taq DNA polymerase     Fermentas 
 
Trifluoroacetic acid (TFA)     Sigma 
 
Tris base       Angus Buffers and Biochemicals 
 
Tween 80 (polyoxyethylenesorbitan monooleate)  Sigma 
 
Yeast Extract       Merck 
 
 
 
 
 
Kits        Manufacturer 
 
Nucleospin Plasmid Kit     Machery-Nagel 
 
GFX PCR DNA Purification Kit    GE Healthcare  
   
DNeasy® Tissue Kit       QIAGEN 
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Equipment       Manufacturer 
 
ÄKTA purifier system     GE Healthcare 
 
Electroporation cuvettes (2 mm gap)    Genetronics 
 
Gene Pulser electroporator     BIO-RAD 
 
JA-10 Beckman rotor      Beckman 
 
JA-14 Beckman rotor      Beckman 
 
NanoDrop ND-1000      NanoDrop Technologies 
 
0.20 μm non-pyrogenic sterile filter    Sarstedt 
 
PCR cycler PTC-200      MJ Research 
 
Quartz cuvettes, 0.1 cm     Hellma 
 
Quartz cuvettes, 1 cm      Hellma 
 
Resource RPC column (3 ml)    GE Healthcare 
 
MR700 Microplate Reader     Dynatech 
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6.3 Primers 
6.3.1 PCR Primers 
 
Primer*  Sequence** 
SakPB:  5’-acactttatgcttccggctcgtatgttgtgt-3’ 
PlnFA: 5’-ccacgcgcgctataggcatggaaaactccacctgt 
   aattgctgttacttc-3’ 
PlnEFim: 5’-cgacagtaatcgatcgtaaagtatattagcatagc-3’ 
Sp6: 5’-tatttaggtgacactatag-3’ 
T7: 5’-taatacgactcactataggg-3’ 
SakP2: 5’-agctatgaccatgattacgccaag-3’ 
AmpF: 5’-gctgtgattattacttttattaatgg-3’ 
AmpR: 5’-ccattaataaaagtaataatcacagc-3’ 
PlnEFXbaIF: 5’–cgacagttctagatcgtaaagtatattagcatagc-3’ 
PlnEFXbalR: 5’-gctatgctaatatactttacgatctagaactgtgc-3’ 
 
 
6.3.2 Mutagenic Primers 
Primer*  Sequence** 
GxxxG-motifs 
PlnF(G30L)F: 5’-cattagcgctgtccgaTTattcatccacg-3’ 
PlnF(G30L)R: 5’-cgtggatgaatAAtcggacagcgctaatg-3’  
PlnF(G30S)F:  5’-cattagcgctgtccgaAgTttcatccacg-3’ 
PlnF(G30S)R: 5’-cgtggatgaaAcTtcggacagcgctaatg-3’ 
PlnF(G30A)F: 5’-cattagcgctgtccgagCattcatccacg-3’ 
PlnF(G30A)R: 5’-cgtggatgaatGctcggacagcgctaatg-3’ 
PlnF(G30K)F: 5’-cattagcgctgtccgaAAattcatccacg-3’ 
PlnF(G30K)R: 5’-cgtggatgaatTTtcggacagcgctaatg-3’ 
PlnF(G30Q)F: 5’-cattagcgctgtccgaCAattcatccacg-3’ 
PlnF(G30Q)R: 5’-cgtggatgaatTGtcggacagcgctaatg-3’ 
 
PlnF(G34L)F: 5’-ggattcatccacTTatagttcaagccatc-3’ 
PlnF(G34L)R: 5’-gatggcttgaactatAAgtggatgaatcc-3’  
PlnF(G34S)F:  5’-ggattcatccacAgTtagttcaagccatc-3’ 
PlnF(G34S)R: 5’-gatggcttgaactaAcTgtggatgaatcc-3’ 
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PlnF(G34A)F: 5’-ggattcatccacgCatagttcaagccatc-3’ 
PlnF(G34A)R: 5’-gatggcttgaactatGcgtggatgaatcc-3’ 
PlnF(G34K)F: 5’-ggattcatccacAAatagttcaagccatc-3’ 
PlnF(G34K)R: 5’-gatggcttgaactatTTgtggatgaatcc-3’ 
PlnF(G34Q)F: 5’-ggattcatccacCAatagttcaagccatc-3’ 
PlnF(G34Q)R: 5’-gatggcttgaactatTGgtggatgaatcc-3’ 
 
Trp/Tyr-residues 
PlnF(Y5W)F:  5’-ggagttttccatgcctGGagcgcgcgtgg-3’ 
PlnF(Y5W)R:  5’-ccacgcgcgctCCaggcatggaaaactcc-3’ 
PlnF(Y5R)F:  5’-ggagttttccatgccAGAagcgcgcgtgg-3’ 
PlnF(Y5R)R:  5’-ccacgcgcgctTCTggcatggaaaactcc-3’ 
PlnF(Y5L)F:  5’-ggagttttccatgcctTAagcgcgcgtgg-3’ 
PlnF(Y5L)R:  5’-ccacgcgcgctTAaggcatggaaaactcc-3’ 
PlnF(Y5F)F:  5’-ggagttttccatgcctTtagcgcgcgtgg-3’ 
PlnE(Y5F)R:  5’-ccacgcgcgctaAaggcatggaaaactcc-3’ 
 
PlnF(Y14W)F: 5’-cgttcggaataattGGaaaagtgctgttgg-3’ 
PlnF(Y14W)R: 5’-ccaacagcacttttCCaattattccgaacg-3’ 
PlnF(Y14R)F: 5’-cgttcggaataatAGAaaaagtgctgttgg-3’ 
PlnF(Y14R)R: 5’-ccaacagcacttttTCTattattccgaacg-3’ 
PlnF(Y14L)F: 5’-cgttcggaataattTAaaaagtgctgttgg-3’ 
PlnF(Y14L)R: 5’-ccaacagcacttttTAaattattccgaacg-3’ 
PlnF(Y14F)F:  5’-cgttcggaataattTtaaaagtgctgttgg-3’ 
PlnE(Y14F)R: 5’-ccaacagcacttttaAaattattccgaacg-3’ 
 
PlnF(W23Y)F: 5’-gttgggcctgccgattATgtcattagcgctg-3’ 
PlnF(W23Y)R: 5’-cagcgctaatgacATaatcggcaggcccaac-3’ 
PlnF(W23R)F: 5’-gttgggcctgccgatAgAgtcattagcgctg-3’ 
PlnF(W23R)R: 5’-cagcgctaatgacTcTatcggcaggcccaac-3’ 
PlnF(W23L)F: 5’-gttgggcctgccgattTAgtcattagcgctg-3’ 
PlnF(W23L)R: 5’-cagcgctaatgacTAaatcggcaggcccaac-3’ 
PlnF(W23F)F: 5’-gttgggcctgccgattTTgtcattagcgctg-3’ 
PlnE(W23F)R: 5’-cagcgctaatgacAAaatcggcaggcccaac-3’ 
*F=forward primer, R=reverse primer 
**Mutagenic positions are in capital letters. The amino acid codon of the new amino acid is marked in green.  
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6.4 Media, Buffers and Agarose Gels 
 
Media 
 
 
LB-medium (0.5 l):     MRS- medium (0.5 l): 
 
5 g NaCl      26 g MRS broth 
5 g peptone 
2.5 g yeast extract     Dissolved inn dH2O to 500 ml. 
       Autoclaved at 112 ºC for 110 min. 
Dissolved in dH2O to 500 ml. 
Autoclaved at 121 ºC for 20 min. 
 
LB-plates (0.5 l):     MRS-plates (0.5 l): 
 
5 g NaCl      26 g MRS broth 
5 g peptone      7.5 g agar 
2.5 g yest extract 
10 g agar      Dissolved in dH2O to 500 ml. 
       Autoclaved at 112 ºC for 10 min. 
Dissolved in dH2O to 500 ml.  After cooled down to ~60 ºC both 
Autoclaved at 121 ºC for 20 min.  erythromycin and chloramphenicol was 
After cooled down to ~60 ºC added to a final concentration of  
erythromycin was added to a final 10 μg/ml. 
concentration of 150  μg/ml. 
 
GM17-medium (0.5 l):  MRSSM-medium (0.11 l): 
 
18.6 g M17 broth  5.2 g MRS broth 
 17.1 g sucrose 
Dissolved in dH2O to 500 ml. 2 g MgCl2 
Autoclaved at 112 ºC for 10 min. 
Addition of Tween 80 to a final  Dissolved in dH2O to 100 ml. 
concentration of 0.1 % (v/v) and  Sterilized by filtrating through 0.2 μm 
glucose to a final concentration  non-pyrogenic sterile filters. 
of 0.4 % (w/v).  
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Buffers 
 
 
Buffer A (1 l):      Buffer B (1 l): 
 
2.48 g NaH2PO4     2.48 g NaH2PO4 
0.26 g Na2HPO4     0.26 g Na2HPO4 
       58.44 g NaCl 
Dissolved in dH2O to 1000 ml. 
Autoclaved at 121 ºC for 20 min.   Dissolved in dH2O to 1000 ml. 
       Autoclaved at 121 ºC for 20 min.  
 
 
Buffer B with 6 M guanidine hydrochloride (100 ml) 
 
0.25 g NaH2PO4 
0.026 g Na2HPO4 
5.84 g NaCl 
56.12 g GuHCl 
 
Dissolved in dH2O to 100 ml. 
Autoclaved at 121 ºC for 20 min. 
 
 
Agarose gel 
 
 
50 x TAE-buffer (1 l):    1 % agarose gel: 
 
254 g Tris base     0.4 g agarose 
57.1 ml glacial acetic acid    50 ml 1 x TAE 
100 ml 0.5 M EDTA (pH 8) 
dH2O to 1 l      Heated in a microwave until agarose was 
       dissolved. 
Autoclaved at 121 ºC for 20 min.   After cooled down to ~60 ºC 3 μl ethi- 
       dium bromide was added. 
                        78 
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